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voor Heit en Mem 
Soms zien ze er als polderjongens uit, met modderige laarzen 
tot hun lies. Soms glanzen ze als meisjes voor een feest, 
geborsteld, opgemaakt en nieuwe kleren aan. Dat doet het 
weer. Dat maakt ze telkens vuil en ook weer schoon. 
Een koppel zwartbonte pinken, kerngezond. Ze komen op 
een drafje naar het hek, een paar attent voorop en eentje sullig 
erachteraan. Ik wacht die laatste altijd af. Het lijkt me sneu 
voor haar als je dat niet zou doen. 
Het beestenspel van duwen, wringen, snuiven, stampen, 
wijken, zwaaien met de kop. Die vreselijke gele dingen in hun 
oor, dat nummer, streepjescode, levenslang. 
Ik bied mijn hand aan en er komt een snuit omhoog, en er 
verschijnt een bleke tong. Maar als ik eerlijk ben: ze hebben 
geen behoefte aan mijn hand, ze zijn nieuwsgierig naar mijn 
hond, veel lager aan het hek, waar snuiven wordt geruild met 
snuffelen. 
De groene ruimte om ons heen. 
Wat moesten we met al dat gras als er geen koeien 
waren? 
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chapter 1 
General introduction 
During the past few decades it has been possible to generate tumor-specific 
cytotoxic Τ lymphocytes (CTL) in vitro from peripheral blood, draining lymph nodes 
and metastatic tumor deposits of human cancer patients. The existence of tumor-
reactive CTL in cancer patients suggests that there is an ongoing, though 
insufficient, immune response to these tumors. Augmentation of the immune response 
may result in more efficient anti-tumor immunity. In murine tumor models, it is 
possible to protect naive animals against subsequent tumor challenge by vaccination 
with irradiated tumor cells (1). Moreover, it is possible to eradicate metastatic tumors 
by adoptive transfer of tumor-reactive Τ lymphocytes (2). 
Despite the successes in animal models, results of immunotherapy in human 
cancer patients are still rather limited. Although responses have been observed in 
patients in various clinical trials, and some of these patients remain in remission for 
several years, most of the responses have been partial and of short duration (3-6). So 
far, most immunotherapy protocols encompassed treatment with cytokines, 
immunization with irradiated tumor cells or adoptive transfer of lymphocyte 
populations without known specificity. These protocols lacked specific targeting of 
the immune system to antigenic determinants on tumor cells. The revolution in 
understanding how Τ lymphocytes recognize antigen, how antigens are processed 
and presented by antigen presenting cells, and the identification of some of the 
antigens recognized, renewed interest in antigen-targeted Τ cell-mediated 
immunotherapy. 
This chapter deals with the array of antigens that recently have been identified 
as targets for anti-melanoma CTL, and focuses on the potential use of melanocyte 
differentiation antigens in immunotherapy protocols of human melanoma. 
Antigen recognition by Τ lymphocytes 
In contrast to В lymphocytes, Τ lymphocytes do not recognize native antigen 
but through their Τ cell receptor (TCR) they recognize antigenic fragments in 
association with highly polymorphic MHC class I or II molecules. CD4+ Τ 
lymphocytes recognize antigenic peptides of 13-18 amino acids in length associated 
with MHC class II molecules (7). MHC class Il-associated peptides are derived from 
exogenous antigens and are presented to CD4+ Τ cells by antigen presenting cells. 
CD8+ cytotoxic Τ cells recognize through their TCR shorter peptide fragments of 9-
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11 amino acids in length, which are presented in the antigen-binding groove of MHC 
class I molecules (8,9). For proper CTL stimulation only a small number of MHC class 
I / peptide complexes are required at the cell surface (10-12). The peptides associate 
in the lumen of the endoplasmic reticulum (ER) with MHC class I heavy chain and 
ß2-microglobulin molecules, followed by transportation of the MHC-peptide 
complex to the cell surface via the trans-Golgi-network (13). MHC class I-presented 
peptides are generated from intracellular protein pools in the cytosol by the 
proteasome, a multi-enzyme complex with proteolytic activity (14). These peptides 
are translocated across the ER membrane by a heterodimer composed of two 
multimembrane spanning proteins, termed Transporter associated with Antigen 
Processing (TAP)-l and -2, which requires the hydrolysis of ATP (15-17). 
CTL 
TCR 7£fcDl CD8 
MHC class I 
proteasome 
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TAP 
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Figure 1. MHC class I processing pathway of endogenous antigens. 
Peptides that bind to a given MHC class I molecule display similarities in amino acid 
composition that have been generalized to peptide-binding motifs. These motifs have 
emerged after sequencing of mixtures of peptides associated with purified MHC class 
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I molecules (18-21), and have later been refined by screening the MHC class I-
binding capacity of large sets of peptides (22-24). Usually, two anchoring residues 
are essential for binding to MHC class I, while other residues within the peptide 
modulate the MHC class I-binding affinity. 
As a consequence of MHC class I processing a representation of the inside of 
the cell is presented to CD8+ Τ lymphocytes at the cell surface. Theoretically every 
intracellular protein from a cell can therefore be presented to cytotoxic Τ 
lymphocytes as multiple peptide fragments in MHC class I molecules. 
Τ cell reactivity in melanoma 
Melanoma is a tumor that originates from melanocytes, the pigment producing 
cells in the skin (cutaneous melanoma) or in the eye (uveal melanoma). The annual 
incidence of melanoma is approximately 6:100.000 persons in the Netherlands, and is 
increasing steadily. Melanoma is an aggressive tumor that rapidly metastasizes. 
Surgery is the standard treatment treatment for primary disease, but effective systemic 
therapy is urgently needed for metastatic disease. 
Several observations indicate that the host immune system can affect the 
course of melanoma. Spontaneous regressions of both the primary tumor as well as 
metastases have been documented (25,26). Furthermore, primary melanomas are 
often infiltrated by mononuclear cells, in particular Τ lymphocytes, a phenomenon 
which is associated with a more favorable prognosis and sometimes with tumor 
regression (25,27). In addition, serum antibodies that react with autologous tumor 
cells (28) as well as anti-tumor cytotoxic Τ lymphocytes (CTL) have been isolated 
from melanoma patients (29-31), demonstrating that both humoral and cellular anti­
tumor immune responses can occur. 
Patient-derived melanoma-reactive CTL have been isolated and cultured in 
vitro from both peripheral blood mononuclear cells (PBMC) (29-31), draining lymph 
nodes (32) and tumor infiltrating lymphocytes (TIL) (33). The majority of these CTL 
are CD8+ Τ lymphocytes that display MHC class I-restricted killing of autologous 
tumor cells. These CTL are designated melanoma-specific because they show no 
reactivity against autologous EBV-transformed В cells, MHC class I-matched 
fibroblasts, or K562 cells, a target cell line that is sensitive to NK cell activity. 
HLA-A*0201 and HLA-A*0101 have most frequently been found as 
restriction elements for anti-melanoma CTL clones (11,34-36). Anti-melanoma CTL 
often display cross-reactivity with allogeneic HLA-A*0201- or HLA-A*0101-
10 
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matched melanomas, implying that shared melanoma antigens are recognized. This 
was further demonstrated by the observation that HLA-A*0201-negative melanoma 
tumor cells became susceptible to lysis by HLA-A*0201 -restricted anti-melanoma 
CTL, upon transfection of the HLA-A*0201-encoding gene (37). 
The elucidation of the role of MHC class I molecules in the recognition of 
target cells by Τ lymphocytes cleared the way to the identification of the antigens 
recognized by anti-melanoma CTL. 
Antigens recognized by anti-melanoma CTL 
Tumor specific antigens 
Several strategies have been followed to unravel the nature of the antigens 
recognized by anti-melanoma CTL. Attempts to identify the target antigens by 
biochemical fractionation of tumor cells have been unsuccessful so far (38,39), with 
the exception of the identification of the underglycosylated MUC-1 antigen. This 
antigen is present on breast and pancreatic carcinomas, and can be recognized by 
patient-derived CTL, both MHC-unrestricted (40,41) and MHC-restricted (42). 
Genetic approaches pioneered in the laboratory of Boon and co-workers have 
proved to be more successful. In order to identify the gene encoding the antigen 
recognized by a particular CTL clone, stable transfectants were generated by 
transfection of a cosmid library prepared with DNA from an autologous melanoma 
cell line. For these transfections an antigen-loss variant of the same melanoma line 
was used as a recipient cell line. Small pools of transfected cells were then screened 
for their ability to stimulate the relevant CTL clone to release tumor necrosis factor 
(TNF) (43). Retrieval of the cosmid encoding the antigen from a positive transfectant 
subsequently led to the identification of the first antigen recognized by anti-
melanoma CTL, the MAGE-1 antigen (44). Later this approach was adapted to a 
method involving the transfection of cDNA libraries into COS cells along with a 
plasmid encoding the relevant restriction element (45). Most of the melanoma 
associated antigens that will be listed below have been identified according to this 
method of cDNA library transfection. 
The MAGE-1 gene is about 5 kb long and comprises two short exons and a 
long third exon. MAGE-1 belongs to a family of twelve closely related genes, all 
located on the X-chromosome (46,47). Expression of the MAGE gene family may be 
developmentally regulated during embryogenesis. The MAGE genes are silent in 
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normal tissues, except for testis. As analyzed by reverse transcriptase PCR, about 
40% of melanoma tumor samples are positive for MAGE-1, whereas approximately 
75% are positive for two other members of the MAGE family, namely MAGE-2 or -3. 
Besides melanomas, a significant proportion of breast tumors, non-small lung tumors 
and head or neck carcinomas express MAGE-1, -2 or -3 (48,49). 
The epitope derived from MAGE-1 recognized by the patients' CTL clone 
used for the identification of the gene was a nonamer presented by HLA-A*0101 
(50). Another CTL clone derived from the same patient recognized a MAGE-1 
encoded peptide in the context of HLA-Cw*1601 (51). Like MAGE-1, the MAGE-3 
gene codes for a tumor antigen presented by HLA-A*0101 (52) and by HLA-
A*0201 (53). 
Other tumor specific genes identified as target antigens for anti-melanoma CTL 
are the BAGE and GAGE genes (54,55). Like the MAGE family, these genes are 
expressed in a variety of tumors but not in normal tissues, except testis. Antigenic 
peptides derived from these antigens could be presented in HLA-Cw*0601 and 
HLA-Cw*1601. Recently, in renal cell carcinoma a CTL-defined antigen, RAGE-1, 
has also been identified with a similar expression pattern (56,57). This antigen is 
silent in normal tissue except for retina. 
Antigens specific for one single tumor may arise from point-mutations in 
genomic coding sequences. Such mutations may cause amino acid changes leading 
to cell surface exposure of novel, tumor specific antigenic peptides. In mouse tumor 
systems it has been demonstrated that point-mutations can generate potent antigens 
that can be recognized by syngeneic Τ lymphocytes (58-60). Recently, the protein 
product of a gene, MUM-1, carrying a point-mutation was identified as a CTL target 
antigen on a melanoma (61). Interestingly, this point-mutation gives rise to an 
antigenic peptide presented by HLA-A*0201 which was located across an exon-
intron junction. In another melanoma a point mutation in a cyclin-dependent kinase 
(CDK4) created an antigenic peptide recognized by HLA-A*0201 restricted CTL 
(62). In this case, expression of the mutated CDK4 presumably contributed to 
malignant transformation by disruption of the cell-cycle regulation. Recently, another 
point mutation in the gene encoding ß-catenin gave rise to an antigenic peptide 
presented by HLA-A*2401 (166). 
Intronic sequences from the gene coding for N-acetylglucosaminyltransferase 
V have also been demonstrated to encode an HLA-A*0201-presented epitope 
recognized by anti-melanoma CTL (167). Remarkably, the mRNA containing the 
intronic sequences was observed to be present in about 50% of melanomas, while in 
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normal tissues only the fully spliced mRNA could be detected. This suggests a 
melanoma specific production of a mRNA encoding the intronic epitope. 
Table I. Tumor specific antigens recognized by anti-melanoma CIL. 
antigen MHC epitope position reference 
MAGE-1 
MAGE-3 
BAGE 
G AGE-1,2 
MUM-1 
CDK4-R24C 
ß-catenin 
GnT-V 
HLA-A*0101 
HLA-Cw*1601 
HLA-A*0101 
HLA-A*0201 
HLA-Cw*1601 
HLA-Cw*0601 
HLA-B*4401 
HLA-A*0201 
HLA-A*2401 
HLA-A*0201 
EADPTGHSY 
SAYGEPRKL 
EVDPIGHLY 
FLWGPRALV 
AARAVFLAL 
YRPRPRRY 
EEKLIVVLF 
ACDPHSGHFV 
SVLDSGIHF 
VLPDVFIRC 
161-169 
230-238 
168-176 
271-279 
2-10 
9-16 
— 
23-32 
29-37 
— 
[44] 
[50] 
[51] 
[52] 
[53] 
[54] 
[55] 
[61] 
[62] 
[166] 
[167] 
Melanocyte differentiation antigens 
Some anti-melanoma CTL lysed in addition to MHC class I-matched allogeneic 
melanoma tumor cells, MHC class I-matched normal melanocytes, suggesting the 
recognition of common melanocyte lineage specific antigens (63). The identification 
of the tyrosinase antigen, a melanosomal protein, as a target for HLA-A*0201 
restricted CTL provided evidence for this hypothesis (45). Furthermore, this 
demonstrated that potentially immunogenic tumor-associated antigens are not 
necessarily mutated or foreign antigens. In addition to two HLA-A*0201 presented 
epitopes, the tyrosinase antigen was found to encode an epitope that could be 
presented by HLA-A*2401 (64,65). 
The gplOO antigen was identified as the second CTL-defined target antigen 
belonging to the category of melanocyte differentiation antigens (66). Based on the 
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correlation between gplOO expression of HLA-A*0201 -positive melanoma tumor 
cells and recognition by a patient derived TIL line, it was investigated whether this 
antigen could serve as a target for anti-melanoma CTL. Reconstitution of CTL 
reactivity following transfection of the cDNA encoding gplOO into gplOO-negative 
melanoma cells identified gplOO as a potential melanoma tumor rejection antigen 
(66). Independently, the gp 100 antigen was identified following a strategy involving 
the isolation of peptides presented by MHC class I molecules at the cell surface of 
melanoma tumor cells (67-69). These peptides were eluted from MHC class I 
molecules by acid treatment. The extracted peptide mixture was fractionated by 
means of HPLC and added back to HLA-A*0201 expressing target cells in CTL 
reconstitution assays. In positive peptide pools further fractionation was 
accomplished by additional HPLC fractionation, followed by tandem mass 
spectroscopy and sequencing of the individual peptides. Apart from the gplOO-
encoded epitope identified following peptide elution (70), four other gplOO derived 
epitopes were found to be recognized by anti-melanoma CTL in the context of HLA-
A*0201 molecules (71-73). 
Two other melanocyte-lineage specific proteins that can be recognized by 
melanoma-reactive CTL are Melan-A/MART-1 and gp75 (74-76). Epitopes derived 
from these antigens could be presented by HLA-A*0201 (Melan-A/MART-1) and by 
HLA-A*3101 (gp75) (76-78). Remarkably, the HLA-A*3101-presented epitope 
encoded by the gp75 gene resulted from translation of an alternative open reading 
frame of 24 aminoacids non-related to the gp75 protein (168). The expression of 
tyrosinase, gplOO, Melan-A/MART-1 and gp75 is limited to melanomas and normal 
melanocytes, as well as to normal retinal tissue that contains pigmented cells. The Τ 
cell epitopes that have been identified so far in these antigens are all encoded by 
non-mutated genes. This is in agreement with the observation that CTL recognizing 
these antigens displayed cross-reactivity with a large panel of HLA-matched 
melanomas. 
Recently, another shared antigen, the ρ 15 antigen was identified as a target for 
HLA-A*2401 restricted anti-melanoma CTL (79). Interestingly, expression of this 
antigen was not restricted to cells of the melanocytic lineage. The levels of RNA 
encoding this antigen appeared to be comparable in melanoma and a variety of 
normal tissues. However, neither autologous fibroblasts nor EBV-transformed В cells 
were recognized by the pl5-reactive CTL, in contrast to a number of HLA-A*2401 
matched melanomas that were recognized. Probably post-transcriptional modification 
of pre-mRNAs encoding the protein or post-translational modification of the protein 
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itself in melanoma cells compared to normal tissue causes differences in cell surface 
exposure of the epitope. 
Table II. Melanocyte differentiation antigens recognized by anti-melanoma CTL. 
antigen 
tyrosinase 
gplOO 
MelanA/MART-1 
gp75 
pl5 
мне 
HLA-A*0201 
HLA-A*0201 
HLA-A*2401 
HLA-B*4401 
HLA-A*0101 
HLA-A*0201 
HLA-A*0201 
HLA-A*0201 
HLA-A*0201 
HLA-A*0201 
HLA-A*0301 
HLA-A*0201 
HLA-A*0201 
HLA-A*3101 
HLA-A*2401 
epitope 
MLLAVLYCL 
YMDGTMSQV 
— 
SEIWRDIDF 
— 
KTWGQYWQV 
ITDQVPGSV 
YLEPGPVTA 
LLDGTATLRL 
VLYRYGSFSV 
ALLAVGATK 
AAGIGILTV 
ELTVILGVL 
MSLQRQFLR 
AYGLDFYIL 
position 
1-9 
369-377 
— 
192-200 
— 
154-162 
209-217 
280-288 
457-466 
476-485 
17-25 
27-35 
32-40 
* 
10-18 
reference 
[45] 
[64] [64,165] 
[65] [164] 
[169] 
[66] 
[72 
[73 
[70 
[71 
[73 
[169] 
[74,75] 
[77] 
[78] 
[76,168*] 
[79] 
Identification of tumor associated CTL-epitopes in absence of established anti­
tumor CTL 
Tumor cell-associated CTL epitopes have also been identified in absence of 
established anti-tumor CTL. Instead, defined antigens have been used as a starting 
point. Based on the idea that every intracellular protein from a malignant cell can be 
presented to Τ lymphocytes in MHC class I molecules, antigens were screened for the 
presence of potential MHC class I-binding peptides. In this respect, allele specific 
peptide-binding motifs proved to be extremely helpful. In addition to their use to 
unravel epitopes within antigens that are known to harbor CTL epitopes (80), these 
15 
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The melanocyte lineage-specific antigen gplOO 
The melanocyte lineage-specific gplOO antigen recognized by mAb NKI-beteb 
is one of the common markers used to diagnose human melanoma (87). NKI-beteb 
reacts with melanoma cells throughout tumor development and does not cross-react 
with other tumor cell types or normal cells, except for melanocytes and pigmented 
cells in the retina. The gplOO antigen is an intracellular glycoprotein of 
approximately 100 kD (87). Recently, a cDNA clone termed gpl00-cl was isolated 
by screening a cDNA expression library constructed from a melanoma cell line. 
Transfection of this cDNA into gplOO-negative cells not only conferred reactivity to 
mAb NKI-beteb, but also to two other mAbs used to diagnose malignant melanoma, 
HMB-40 and HMB-50 (88). Characterization of the gpl00-cl cDNA revealed that 
gplOO is a type I transmembrane glycoprotein highly homologous to another 
melanocyte specific protein, Pmell7 (89,90). Nucleotide sequence analysis of 
genomic DNA indicated that the transcripts corresponding to the gplOO and Pmell7 
cDNAs originate from a single gene via alternative splicing (90). In all malignant and 
normal melanocytic cells analyzed, gplOO and Pmell7 RNAs are simultaneously 
expressed. A biological function for the melanosomal gplOO and Pmell7 proteins is 
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as yet unknown, but it is likely that they are involved in the process of melanization, 
either as enzymes or as structural components of the melanosome. 
Besides its value as a tumor marker, the gplOO antigen was identified as a 
potential tumor-rejection antigen that can be recognized by anti-melanoma CTL. 
Several CTL lines derived from melanoma tumor material as well as from peripheral 
blood lymphocytes of patients displayed specificity for gplOO-derived epitopes 
presented in HLA-A*0201 (66,70,77). Transfection of either the gplOO- or the 
Pmell7-encoding cDNA into gplOO / Pmell7-negative HLA-A*0201-positive BLM 
cells resulted in susceptibility for lysis by anti-gplOO CTL (91). This implies that 
processing of both proteins can generate immunogenic peptides presented in HLA-
A*0201. Since melanoma cells express gplOO and Pmell7 mRNA simultaneously, 
processing of both gplOO and Pmell7 will contribute to the total amount of 
immunogenic peptides presented at the cell surface. 
Immunogenicity of melanocyte differentiation antigens 
The array of CTL epitopes derived from gplOO and other melanocyte lineage-
specific antigens, and the recognition of some of these epitopes by CTL of several 
melanoma patients, emphasizes the immunogenicity of these antigens. The 
immunogenicity of melanocyte differentiation antigens may explain the clinical 
observation that melanoma patients often display local depigmentation of their skin 
(vitiligo) (92). The occurrence of vitiligo in melanoma patients has been reported to 
correlate with prolonged survival (92) and may result from the destruction of 
melanocytes as a consequence of an immune response directed against melanocyte 
differentiation antigens (93). Other clinical data, indicating that vitiligo is associated 
with improved survival of melanoma patients (94), support the notion that melanoma 
patients may benefit from an immune response against melanocyte lineage-specific 
antigens. 
Adoptive transfer of TIL plus IL-2 resulted in regression of metastatic 
melanoma in a number of patients (3). Moreover, therapy with gplOO-reactive TIL 
1200 lymphocytes was associated with objective tumor regression in the autologous 
patient (71), strongly suggesting that CTL directed against melanocyte 
differentiation antigens can cause tumor regression in vivo. The gplOO antigen may 
be of particular interest with respect to immunotherapy of melanoma since adoptive 
transfer of four gplOO-reactive TIL lines, but not of six other Melan A / MART-1-
17 
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reactive TIL, resulted in tumor regression when infused into the autologous patients 
along with IL-2 (73). 
Since melanocyte differentiation antigens like gp 100 are widely expressed in 
melanoma tumor cells, they may constitute useful targets for specific immunotherapy 
against melanoma. No unwanted toxicity was observed in the autologous patient 
upon TIL 1200 treatment (71). However, adverse side effects upon gplOO 
immunization, such as the destruction of normal melanocytic cells and retinal pigment 
epithelium cells, remain possible and require further detailed study. 
Ь the immune system tolerized for melanocyte differentiation antigens? 
Considering the fact that melanocyte differentiation antigens are self antigens, 
questions regarding the state of tolerance of the immune system with respect to these 
antigens arise. The thymus is the major site where Τ cell-tolerance induction and self-
nonself discrimination occurs. With respect to self antigens expressed in the thymus, 
clonal deletion is the predominant mechanism to eliminate self-reactive Τ cells (95). In 
contrast, for organ-specific self antigens that are inaccessible to the circulation, like 
the melanocyte-lineage specific antigens, Τ cell-tolerance may be induced and 
maintained in the periphery or may not be induced at all. In the latter case, functional 
inactivation of self-reactive Τ cells does not occur and these mature Τ cells exist in 
the periphery as innocent or ignorant Τ cells (96). 
For melanocyte differentiation antigen-reactive Τ cells one could speculate 
that T-cell tolerance might have been induced for Τ cells reactive with these antigens 
that have a high affinity TCR for MHC class I-peptide complexes. In line with this, 
some CTL reactive with melanocyte differentiation antigen derived epitopes display 
only intermediate TCR affinity, as assessed by the amount of peptide needed for 
target cell sensitization (64,71,73,77,78). However, this may in part reflect the affinity 
of the epitopes for MHC class I. Analysis of HLA-A*0201-binding affinities of all 
CTL-defined melanocyte differentiation antigen derived epitopes revealed a range of 
intermediate to high affinity for HLA-A*0201 (73). The existence of CTL with high 
affinity TCR for the gplOO 280-288 epitope argues against tolerizing mechanisms for 
Τ cells reactive with melanocyte differentiation antigens. Despite the fact that this 
epitope has an intermediate affinity for HLA-A*0201, it was recognized by several 
CTL lines when applied at concentrations as low as 1 to 10 pM (70). 
It is likely that melanocyte lineage-specific antigen-reactive Τ lymphocytes 
have not been anergized and exist in the periphery as quiescent Τ cells. As a 
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consequence induction of anti-melanoma Τ cell reactivity against melanocyte 
lineage-specific antigens does not imply the 'breaking' of self-tolerance, but rather 
involves the activation of ignorant self-reactive Τ lymphocytes. This notion readily 
fits in Polly Matzingers' theory, in which she proposes that the immune system is not 
as such adapted to discriminate between self and non-self, but that its primary driving 
force is to detect and protect against danger resulting from damaged tissues (97). 
Feasibility of immunotherapy in melanoma patients employing shared tumor-
associated antigens 
The identification of broadly expressed potential tumor rejection antigens, in 
combination with the existence of patient derived anti-tumor CTL, raises the 
question of why in most cancer patients an adequate immune response is not 
mounted in vivo. The growth of tumors even though they express immunogenic 
determinants could reflect ineffective presentation of tumor antigens by antigen 
presenting cells resulting in a failure to activate antigen specific Τ lymphocytes. If 
however, an anti-tumor immune response is initiated, tumors still escape the immune 
response presumably by releasing immune-suppressive factors (98). Alternatively, 
tumors may escape the immune response by masking their immunogenic 
determinants. This could be accomplished by selection of either antigen-loss variants 
or by down-modulation of MHC class I molecules or molecules involved in antigen 
processing (99-104). 
Most likely immunotherapy will not be able to eradicate large tumor masses. 
However, antigen-targeted immunotherapy may be effective in the adjuvant setting, 
in which tumor-induced immunosuppression could be decreased. Since target 
antigens as well as Τ lymphocytes in the patients' Τ cell repertoire are now available, 
accomplishment of adequate in vivo initiation of anti-tumor immunity will be of 
critical importance. 
Induction of anti-tumor immunity 
At the onset of classical immune responses, soluble antigen is acquired and 
processed by professional antigen presenting cells; MHC class II + В lymphocytes, 
macrophages or dendritic cells. MHC class II-mediated presentation to antigen-
specific CD4+ helper Τ lymphocytes subsequently results in activation of helper Τ 
cells. Activated CD4+ helper Τ lymphocytes now provide 'help' to antigen-specific 
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CD8 + Τ lymphocytes in the form of secreted cytokines. Recruited and activated 
effector CD8 + Τ lymphocytes can then eliminate target cells presenting 
endogenously synthesized antigenic peptide in the context of MHC class I 
molecules. 
The concept of CD4+ helper Τ cell-mediated induction of anti-tumor immunity 
is critically dependent on the availability of tumor derived antigens. If tumors do not 
secrete antigenic molecules or when tumor cell debris is not produced, antigenic 
tumor peptides will not gain access to the MHC molecules of professional antigen 
presenting cells. During the early stages of tumor development minimal tumor cell 
death occurs, therefore the lack of proper CD4+ Τ lymphocyte activation may 
hamper induction of an appropriate anti-tumor immune response (105). Later in 
tumor progression, when cellular debris is produced by necrosis or by local 
inflammatory reactions, a delayed immune response can be initiated. However, in 
most cases this response will be insufficient to eradicate the established tumor. 
In melanoma the role of Τ helper cells in anti-tumor responses is exemplified by 
the occurrence of CD4+ Τ lymphocytes reactive with MHC class II + tumor cells 
(106-111). Interestingly, CD4+ Τ lymphocyte reactivity to the tyrosinase antigen has 
been reported (112), indicating that melanocyte differentiation antigens can be 
targets for both MHC class I- and class II-restricted Τ lymphocytes. 
Strategies to enhance in vivo induction of anti-tumor immunity 
To circumvent the need for professional antigen presenting cells for tumor 
antigen presentation, strategies were developed to genetically modify tumor cells so 
that they could directly present antigen to Τ lymphocytes. It is generally accepted 
that for full Τ lymphocyte activation, stimulation by peptide-МНС complexes via the 
Τ cell receptor alone is not sufficient. In addition, costimulatory signals provided by 
professional antigen presenting cells are needed for proper Τ cell stimulation. The 
CD28 molecule on Τ lymphocytes has been identified as the major costimulatory 
receptor. This receptor interacts with B7-1 (CD80) and B7-2 (CD86) antigens whose 
expression is limited to professional antigen presenting cells (113,114). Several 
reports have demonstrated that the immunogenicity of tumors could be enhanced by 
the introduction of the B7-1 molecule into tumor cells. In murine tumor models B7-1 
transfected tumor cells have been shown to be rejected by syngeneic mice. 
Moreover, this rejection could result in immunity to a challenge with the parental, 
untransfected tumor (115-119). Inactivation of B7-1-transfected tumors by irradiation 
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The role of dendritic cells in MHC class I-dependent Τ lymphocyte responses 
Dendritic cells are found in low numbers in tissues and lymphoid organs and 
are present in the skin as Langerhans cells. Dendritic cells originate from 
haematopoietic stem cells, although their stages of differentiation from progenitors 
are poorly understood (129,130). Dendritic cells can acquire antigens in the 
periphery and migrate via the afferent lymph or bloodstream to the Τ cell dependent 
areas of lymphoid organs. Here presentation of acquired and processed antigen to Τ 
lymphocytes occurs, leading to the initiation of immune responses (131-133). 
The hallmark of dendritic cells is their ability to prime naive Τ lymphocytes. 
The efficiency with which dendritic cells prime naive Τ cells has been attributed to 
high expression levels of MHC class I, class II and costimulatory molecules, and the 
capacity of these cells to cluster large numbers of Τ cells (134-136). Next to being 
strong stimulators in the mixed lymphocyte reaction (134), dendritic cells have been 
shown to be potent inducers of antigen-specific immune responses. When pulsed 
with MHC class I-restricted epitopes, dendritic cells were able to induce strong CTL 
responses in vitro (137-140) and in vivo (141). In dendritic cell-mediated induction of 
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anti-viral responses, proliferation of antigen-specific CD4+ Τ cells significantly 
augmented the development of CTL responses (137,138,142). 
In vitro induction of virus-specific primary CTL responses has been achieved 
using dendritic cells as antigen presenting cells that were either infected with virus or 
were exogenously loaded with MHC class I-binding synthetic peptides. Dendritic 
cells pulsed with total viral antigen were a poor stimulus for the development of CTL 
(137). Apparently, dendritic cells have no efficient mechanism for the uptake and 
delivery of exogenous antigen into the MHC class I-processing pathway. 
Circumventing strategies to accomplish MHC class I-mediated presentation of 
exogenous antigen by dendritic cells have included direct antigen delivery to the 
cytoplasm of dendritic cells via osmotic lysis of pinocytotic vesicles or via uptake of 
pH-sensitive liposomes. In this manner primary CTL could be induced both in vivo, in 
a murine model system using ovalbumin as antigen, and in vitro, using human PBL 
and keyhole limpet hemocyanin as antigen (143,144). Another approach uses the 
pore forming capacity of a bacterial toxin, listeriolysin, for the entry of proteins into 
the MHC class I-processing pathway (145). Alternatively, de novo synthesis of the 
desired antigens by dendritic cells was accomplished via transfection or viral 
transduction of antigen encoding DNA, thus leading to MHC class I presentation 
(146, and H. Spits, personal communication). 
Dendritic cells as inducers of anti-tumor immune responses 
As well as being potent inducers of anti-viral CTL responses, dendritic cells 
might also play a pivotal role in the induction of Τ cell-mediated anti-tumor 
responses. A suggestion supporting the importance of dendritic cells in this respect 
comes from the clinical observation that infiltration of presumptive dendritic cells into 
tumor tissue seems to correlate with a favorable clinical prognosis (147-151). 
Several groups have reported the induction of MHC class II mediated immune 
responses after stimulation with tumor antigen-pulsed dendritic cells in vitro and in 
vivo (132,152). In addition, dendritic cells pulsed with tumor antigen in vitro have 
been shown to induce tumor resistance in vivo (153-155). Recently, it was 
demonstrated that intravenous injection of in vitro isolated dendritic cells pulsed 
with a single MHC class I restricted CTL epitope induced a protective CTL response 
in vivo. The vaccinated mice were resistant to a subsequent challenge with tumor 
cells expressing the relevant epitope (156). Moreover, eradication of established 
tumors could be achieved using peptide-loaded dendritic cells in the same and two 
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other murine tumor models (157,158). Interestingly, in the identical system 
therapeutic effects could be observed when dendritic cells were pulsed with tumor-
derived crude peptide extracts as well as with synthetic peptide (W.J. Storkus, 
personal communication). 
Based on the data obtained from murine models, it is tempting to speculate 
that administration of dendritic cells may also be effective in generating cellular anti­
tumor immunity in patients. Recently, it was reported that upon injection of dendritic 
cells loaded with a melanoma CTL epitope into melanoma patients, tumor-specific 
CTL could be isolated from the vaccination site and adjacent tumor tissue (159). This 
indicates that indeed peptide-specific CTL have been induced by dendritic cells in 
vivo. In addition, vaccination of patients with В cell lymphoma using autologous 
antigen-pulsed dendritic cells resulted in measurable anti-tumor immune responses in 
four out of four patients treated (160). In addition, in this study clinical responses, 
including one complete response, were observed. 
Until recently, the use of dendritic cells as immuno-therapeutical agents has 
been hampered by their low frequency in the peripheral blood compartment, causing 
great difficulty in obtaining sufficient amounts of pure dendritic cells. However, it has 
recently become possible to generate sizeable numbers of pure human dendritic cells, 
by culturing progenitor cells from peripheral blood in the presence of GM-CSF and 
IL-4 (161,162). It was demonstrated that using such dendritic cells, CTL responses 
could be elicited in vitro from healthy donor peripheral blood lymphocytes directed 
against melanoma associated antigen derived epitopes (163). The next step would be 
to generate large amounts of dendritic cells in vitro, expose them to antigen and 
reinfuse them into patients. This promising immunotherapeutic concept will be 
applied in the near future employing broadly expressed antigens in melanoma. In 
addition, a similar approach may be applicable to other solid tumors using the p21ras 
and p53 antigens. 
Scope of this thesis 
This thesis deals with the identification of the melanocyte differentiation 
antigen gplOO as a potential tumor rejection antigen. Chapter 2 describes the 
identification of the gplOO antigen as a target antigen for melanoma patient-derived 
tumor infiltrating lymphocytes. Based on the correlation between gplOO expression 
of HLA-A*0201+ melanoma tumor cells and recognition by TIL 1200, a CD8+ Τ cell 
line derived from a melaonma metastasis, we explored whether transfection of the 
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gplOO encoding cDNA into gplOO" target cells could restore CTL reactivity. Using 
murine and human stable transfectants we demonstrated that indeed gplOO was the 
antigen recognized. After tyrosinase, gplOO was the second melanocyte lineage-
specific antigen identified as a melanoma-associated CTL target. 
In chapter 3 we demonstrate that the oligoclonal TIL 1200 line recognized 
two peptides derived from gplOO presented in the context of HLA-A*0201. In 
addition to a 10-mer peptide located at position 457-466 in the gplOO protein, we 
identified another epitope located at position 154-162 that induced TIL 1200 
reactivity. This epitope could be recognized at a hundredfold lower concentration 
compared to the 457-466 epitope and was therefore regarded as the major epitope 
derived from gplOO recognized by TIL 1200. 
Since gplOO and Pmell7 are highly homologous and simultaneously 
expressed in all malignant and normal melanocytic cells analyzed, we investigated 
whether both proteins had similar properties regarding their immunogenicity. In 
chapter 4 we describe that cells transfected with the pMell7 encoding cDNA also 
react with all three anti-gplOO mAbs; NKI-beteb, HMB-45 and HMB-50. 
Furthermore, we show that pMell7 transfectants are specifically lysed by TIL 1200, 
demonstrating that processing of both gplOO and pMell7 gives rise to peptides seen 
by anti-melanoma CTL. Therefore, both gplOO and Pmell7 are potential targets for 
immunotherapy of malignant melanoma. 
By employing peptide-loaded dendritic cells, generated from peripheral blood 
monocytes of healthy donors, we demonstrate in chapter 5 the induction of 
melanoma-associated antigen-specific CTL in vitro. CTL were induced directed 
against HLA-A*0201 presented epitopes derived from tyrosinase, gplOO and Melan-
A/MART-1, indicating that the Τ cell repertoire is capable of generating responses 
against these differentiation antigens. 
Chapter 6 deals with the optimization of peptide epitopes derived from the 
melanocyte differentiation antigens Melan-A/MART-1 and gplOO. In order to 
increase the immunogenicity of two epitopes derived from these antigens, single 
amino acid-substituted epitope-analogues displaying increased affinity for HLA-
A*0201 were tested for their capacity to induce melanoma-reactive CTL. 
Finally, in chapter 7 our findings are discussed in relation to the prospects and 
drawbacks of antigen-targeted immunotherapy of melanoma. 
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Summary 
We recently isolated a cDNA clone that encodes the melanocyte lineage-
specific antigen gplOO. Antibodies directed against gplOO are an important tool in 
the diagnosis of human melanoma. Since the gp 100 antigen is highly expressed in 
melanocytic cells, we investigated whether this antigen might serve as a target for 
anti-melanoma cytotoxic Τ lymphocytes (CTL). Here, we demonstrate that cytotoxic 
tumor infiltrating lymphocytes (TIL) derived from a melanoma patient (TIL 1200) are 
directed against gplOO. HLA-A2.1+ melanoma cells are lysed by TIL from this 
patient. In addition, murine double transfectants, expressing both HLA-A2.1 and 
gplOO, are lysed by TIL 1200, whereas transfectants expressing only HLA-A2.1 are 
not susceptible to lysis. Furthermore, the HLA-A2.1+ melanoma cell line BLM, which 
lacks gplOO expression and is resistant to lysis, becomes susceptible after 
transfection of gplOO cDNA. Finally, HLA-A2.1+ normal melanocytes are lysed by 
TIL 1200. These data demonstrate that the melanocyte differentiation antigen gplOO 
can be recognized in the context of HLA-A2.1 by CTL from a melanoma patient. 
GplOO may therefore constitute a useful target for specific immunotherapy against 
melanoma, provided that no unacceptable cytotoxicity towards normal tissue is 
observed. 
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Introduction 
The melanocyte lineage-specific antigens recognized by mAb NKI-beteb are 
among the best diagnostic markers for human melanoma available to date (1). NKI-
beteb reacts with melanoma cells throughout tumor development and does not cross-
react with other tumor-cell types or normal cells, except for melanocytes and 
pigmented cells in the retina. The antigen recognized by mAb NKI-beteb is an 
intracellular glycoprotein of approximately 100 kD (gplOO) (1). Recently, we isolated 
a cDNA clone termed gpl00-cl, which not only confers reactivity to mAb NKI-beteb, 
but also to two other mAbs used in diagnosis of malignant melanoma, HMB-SO and 
HMB-45 (2). Characterization of the gpl00-cl cDNA revealed that gp 100 is a type I 
transmembrane glycoprotein highly homologous to another melanocyte specific 
protein, Pmell7 (Adema, G.J., A.J. de Boer, A.M. Vogel, W.A.M. Loenen, and C.G. 
Figdor, manuscript submitted for publication). 
Although the mAbs recognizing gplOO are widely used for diagnostic 
purposes, they are less well applicable for therapeutic use since gplOO is 
predominantly expressed intracellularly. However, it has now been clearly 
demonstrated that intracellular proteins can be processed and presented as peptides 
in association with MHC molecules to Τ lymphocytes (3,4). Therefore, the gplOO 
antigen is a potential target for cellular immune responses against melanoma. CTL 
recognizing melanoma tumor cells in a Τ cell receptor dependent and MHC restricted 
manner have been isolated from tumor bearing patients (for a review see reference 
(5)). These CTL often display cross-reactivity with allogeneic HLA-A2.1 matched 
melanomas, implying that shared melanoma antigens presented in the context of 
HLA-A2.1 are recognized (6,7). Recently, it has been reported that some CTL not 
only react with melanoma tumor cells, but also with normal melanocytes, suggesting 
recognition of differentiation antigens expressed by melanocytes (8). 
Several approaches have been followed to unravel the nature of the antigens 
recognized by anti-melanoma CTL (9,10). However, the identity of the antigens 
remains largely unknown. So far, only a genetic approach applied by Boon and 
colleagues has resulted in the identification of antigens recognized by CTL (9,11). 
We have chosen to follow a reversed approach in that we focused on a well defined 
melanocytic antigen, the gplOO antigen, and investigated whether this antigen can 
serve as a target for anti-melanoma CTL. 
Here, we demonstrate that the melanocyte differentiation antigen gplOO is 
specifically recognized by melanoma derived TIL in the context of HLA-A2.1. 
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Materials and methods 
Cell Culture. TIL were generated by growth of single cell suspensions of 
metastatic melanomas with 1000 U/ml IL-2 (Cetus Corp., Emeryville, CA) and were grown as 
was described previously (7). Melanoma lines Mel 397 and Mel 624 were obtained and grown 
as was reported previously (7). HLA-A2.1"1" melanoma lines MEWO (12) and BLM (13) and 
murine P815 transfectants were grown in DMEM (Gibco, Paisley, Scotland UK) + 7.5% heat-
inactivated FCS (Gibco). JY, KS62 and murine EL4 transfectants were cultured in Iscoves 
medium (Gibco) + 7.5% FCS. Murine cells were grown in the presence of 5.10-5 Μ ß-
mercapto-ethanol and all media contained antibiotics. Isolation of normal melanocytes from 
foreskin was performed by the method of Eisinger and Marko (14) with modifications as 
described previously (15). Melanocytes from passages two to three were used in chromium 
release assays. 
DNA Constructs and Transfection. Plasmid pBJlgplOOneo was obtained by cloning 
the Eco RI fragment of the lambda gpl00-cl cDNA clone (2) in the coding orientation in the 
polylinker of pBJl-neo (16). Plasmid pBA2 containing a genomic fragment encoding HLA-
A2.1 and human ß-2 microglobulin was kindly provided by E.J. Baas (The Netherlands 
Cancer Institute, Division of Biochemistry, Amsterdam, the Netherlands). Plasmid pGK-hyg 
contains the hygromycin phosphotransferase gene (17). For the introduction of the HLA-A2.1 
and ß-2 microglobulin genes, EL4 cells were transfected with 18 μ% of pBA2 and 2 μg of 
pGK-hyg DNA according to the calcium phosphate coprecipitation procedure (18) using 
Calciumphosphate Transfection Systems (BRL, Gaithersburg, MD). Twenty-four hours after 
transfection 500 μg/πll hygromycin В (Calbiochem, La Jolla, CA) was added to the medium 
for selection of stable transfectants. HLA-A2.1 + gpl00+ EL4 cells were obtained by 
transfection of stable HLA-A2.1+ EL4 clones with 20 μg of pBJl-gplOO DNA and were 
selected with 500 μg/ml hygromycin В and 1 mg/ml G418 (Gibco, Paisley, Scotland UK). 
BLM cells were transfected with 20 μg of pBJl-gplOOneo DNA by calcium phosphate 
coprecipitation and were selected with 1 mg/ml G418. P815 A2.1 and P815 A2.1/gpl00 cells 
were kindly provided by P. Coulie (Ludwig Institute, Brussels, Belgium). 
MAb and Flow Cytometry. Phenotypic analysis of melanomas, transfec-tants and 
normal melanocytes was performed by indirect immuno-fluorescence followed by flow 
cytometry using a FACScan® (Becton Dickinson, Mountain View, CA). Purified anti-gplOO 
mAb NKI-beteb (1), and anti-HLA-A2 mAbs BB7.2 (culture supernatant) (19) and MA2.1 
(ascites 1:500 dilution) (20) were used as primary reagents. FITC conjugated GAM-IgG-
F(ab')2 (Zymed, San Francisco, CA) was used for the second incubation. For the detection of 
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the intracellular gplOO antigen cells were permeabilized in 0.01% digitonin and were 
subsequently fixed in 1% paraformaldehyde. 
Chromium Release Assay. Chromium release assays were performed as described 
previously (7). Briefly, 106 target cells were incubated with 100 цСі Na251CrC>4 (Amersham, 
Bucks, UK) for 1 hour. Various amounts of effector cells were then added to 2.103 target cells 
in triplicate wells of U bottomed microtiter plates (Costar, Badhoevedorp, The Netherlands) in 
a final volume of 150 μΐ. After 5 hours of incubation part of the supernatant was harvested and 
its radioactive content was measured. Target cells were incubated for 48 hours with 50 U/ml 
human (Boehringer, Ingelheim, Germany) or mouse recombinant IFNy (TNO, Rijswijk, The 
Netherlands) prior to use in chromium release assays. 
Results and Discussion 
In search of gplOO-specific CTL we focused on HLA-A2.1 as a restriction 
element because of its widespread occurrence in Caucasians and its presumptive 
dominant role in CTL reactivity against melanoma. A HLA-A2.1+ TIL line, TIL 1200, 
was used for this study. This TIL line expresses TCR αβ, CD3 and CD8 (data not 
shown). 
HLA-A2.1 Restricted Killing of Melanoma Tumor Cells by TIL 1200 
Corresponds with gplOO Expression. Cytolytic activity of TIL 1200 was 
analyzed using a panel of human melanoma cell lines. As shown in Figure 1, TIL 1200 
efficiently lyses HLA- A2.1 + Mel 624 and MEWO melanoma tumor cells which both 
express gplOO, whereas no reactivity towards HLA-A2.1" gpl00 + Mel 397 cells was 
observed. Interestingly, we observed that also HLA-A2.1+ BLM melanoma cells are 
resistant to lysis by TIL 1200 (Fig. 1). Previously, we showed that BLM cells have 
lost the expression of the gplOO antigen, both at the protein and at the mRNA level 
(2). Furthermore, HLA-A2.1+ EBV transformed В cells (JY), which also lack gplOO 
expression, and K562 cells were not lysed by TIL 1200 (data not shown). Together, 
these data demonstrate that TIL 1200 displays HLA-A2.1 restricted killing which 
correlates with gplOO expression. 
TIL 1200 Recognizes HLA-A2.1+ gpl00+ Transfectants. To explore whether 
TIL 1200 recognized a gplOO derived peptide in the context of HLA-A2.1, we co-
transfected murine EL4 cells with a genomic fragment encoding HLA-A2.1 together 
with a plasmid conferring hygromycin resistance. Stable hygromycin-resistant 
transfectants were selected, and analyzed for HLA-A2.1 surface expression by flow 
cytometry. EL4 cells expressing HLA-A2.1 (EL4 A2.1) were subsequently 
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20 30 
E/T ratio 
Figure 1. HLA-A2.1 restricted 
killing of gpl00+ melanoma 
tumor cells by TIL 1200. Lysis of 
chromium-labelled cells was 
measured after 5 hours. All 
melanoma cell lines except BLM 
express the gplOO antigen. One 
representative experiment out of 
three is shown. 
Mel 624 HLAA2.1+ gpl00+ 
Mewo HLAA2.1+ gpl00+ 
BLM HLAA2.1+ gplOO-
Mel397 HLAA2.1- gpl00+ 
transfected with pBJl-gplOOneo, which encodes gplOO and confers resistance to 
G418. Stable transfectants were selected and were screened for gplOO expression 
using mAb NKI-beteb (EL4 A2.1/gpl00). In collaboration with P. Coulie (Ludwig 
Institute, Brussels, Belgium) a similar panel of transfectants was generated in murine 
P815 cells (P815 A2.1 and P815 A2.1/gpl00). Using these murine transfectants as 
target cells in chromium release assays, we clearly observed gplOO specific lysis by 
TIL 1200 (Fig. 2A and 2B). The percentage of specific lysis (25-35%, E/T 30 : 1) of 
murine EL4 A2.1/gpl00 and P815 A2.1/gpl00 transfectants by TIL 1200 was 
somewhat lower compared to that observed with the HLA-A2.1+ gpl00+human 
melanoma cells (45-60%, E/T 30 : 1). This difference may be explained by non-
matched accessory molecules between human TIL and murine transfectants. To 
overcome this we introduced the gplOO antigen into human HLA-A2.1+ gplOO" 
BLM melanoma cells by transfection of pBJl-gplOOneo. Stable BLM gplOO clones 
were tested in chromium release assays using TIL 1200. As shown in Figure 2C, 
BLM gplOO clones H2.3 and 5A3 were as sensitive to lysis by TIL 1200 as Mel 624 
and MEWO cells which express the gplOO antigen endogenously. The gplOO 
specificity of TIL 1200 was further demonstrated by the absence of lysis of G418 
resistant BLM cells not expressing gplOO, excluding the possibility that neomycin 
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derived peptides are recognized (data not shown). We conclude from these data that 
TIL 1200 recognizes a gplOO derived peptide presented in HLA-A2.1. 
20 30 
E/T ratio 
EL4A2.1 
EL4A2.1/gpl00 
P815A2.1 
P815A2.1/gpl00 
10 20 30 
E/T ratio 
BLM 
BLM gplOO H2.3 
BLMgpl00 5A3 
Figure 2. Lysis of HLA-A2.1+ gpl00+ transfectants by TIL 1200. Murine EL4 and P815 cells 
were transfected with both gplOO and HLA-A2.1 DNA, and human BLM cells were transfected 
gplOO DNA as described in Materials and Methods. Isolated clones were tested for sensitivity to 
lysis by TIL 1200. Figure 2A and 2B are representative examples of experiments performed with 
four individual EL4 A2.1/gpl00 and P815 A2.1/gpl00 clones. In Figure 2C one experiment out 
of three, using BLM gplOO clones H2.3 and 5A3, is shown. 
HLA-A2.1+Normal Melanocytes Are Lysed by TIL 1200. Since gplOO is 
expressed in all cells of the melanocytic lineage one would predict that also normal 
melanocytes are recognized by TIL 1200. To investigate this, short term cultures of 
HLA-A2.1+ and HLA-A2.1" normal melanocytes were tested for lysis by TIL 1200. 
Melanocytes used in this study all expressed the gplOO antigen to a similar extent 
(data not shown). HLA-A2.1"1" melanocytes were efficiently lysed, whereas HLA-
A2.1" melanocytes were resistant to lysis by TIL 1200 (Fig.3). These results 
demonstrate that TIL 1200 is also reactive with gplOO derived peptides presented in 
HLA-A2.1 by normal melanocytes. 
Lysis of HLA-A2.1"1" gpl00+ melanocytes rules out the possibility that TIL 
1200 recognizes a peptide epitope of gplOO mutated in melanoma tumor cells. This is 
further demonstrated by the fact that TIL 1200 is reactive with several allogeneic 
HLA-A2.1 matched, gplOO"1" melanoma tumor lines. We therefore conclude that TIL 
1200 recognizes a non-mutated peptide derived from the melanocyte differentiation 
antigen gplOO expressed by melanoma tumor cells as well as by normal melanocytes. 
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Figure 3. Lysis of HLA-A2.1 + 
normal melanocytes by TIL 1200. 
Short term cultures of foreskin 
derived melanocytes were tested for 
sensitivity to lysis by TIL 1200. 
Expression of HLA-A2.1 was 
analyzed by flow cytometry using 
mAbs BB7.2 (19) and MA2.1 (20). 
— · — melanocytes 1 HLAA2.1+ 
— * — melanocytes 2 HLAA2.1+ 
— о — melanocytes 3 HLAA2.1-
—Δ— melanocytes 4 HLAA2.1-
Furthermore, our data show that gplOO can be immunogenic, suggesting that 
melanocyte differentiation antigens may serve as tumor rejection antigens. This 
hypothesis is strengthened by : 1) the finding that antibodies directed against this 
type of antigens (e. g. gp75) are present in the serum of melanoma patients (21,22); 2) 
the recent observation that several anti-melanoma CTL display cross-reactivity with 
normal melanocytes (8); and 3) the identification of the melanocyte lineage-specific 
tyrosinase protein as a target for anti-melanoma CTL (23). Immunogenicity of 
melanocyte differentiation antigens may also explain the clinical observation that 
melanoma patients often display local depigmentation of their skin (24). The 
occurrence of local depigmentation in melanoma patients has been reported to 
correlate with prolonged survival (24) and may result from the destruction of 
melanocytes as a consequence of an immune response directed against melanocyte 
differentiation antigens (25). Other clinical data, indicating that vitiligo (local 
depigmentation of the skin) is associated with improved survival of melanoma 
patients (26), are in line with this hypothesis. TIL have been shown to mediate 
regression of metastatic melanoma in patients treated with TIL plus IL-2 (27). Of 
particular interest is the fact that therapy with TIL 1200 was associated with 
objective tumor regression in the autologous patient (Rosenberg, S.A., unpublished 
data), suggesting that CTL directed against melanocyte differentiation antigens can 
cause tumor regression in vivo. 
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Since melanocyte differentiation antigens like gplOO are widely expressed in 
melanoma tumor cells, they may constitute a useful target for specific immunotherapy 
against melanoma. Although no unwanted toxicity was observed in the autologous 
patient upon TIL 1200 treatment, adverse side effects upon gplOO immunization, 
such as the destruction of normal melanocytic cells and retinal pigment epithelium 
cells, remain a possibility and require further study in animal models. Furthermore, it 
will be important to determine how widely Τ cell mediated gplOO-reactivity is 
observed in melanoma patients. 
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Summary 
Cytotoxic Τ lymphocytes (CTL) reactive with human melanoma tumor cells 
occasionally display cross-reactivity with normal melanocytes. Previously, we 
identified the melanocyte lineage-specific antigen gplOO, that is expressed by both 
melanoma cells and normal melanocytes, as a target antigen for tumor infiltrating 
lymphocytes derived from a melanoma patient (TIL 1200). Here, we demonstrate that 
the oligoclonal HLA-A2.1 -restricted TIL 1200 line is reactive with two distinct 
peptides derived from the gplOO protein. Apart from the peptide corresponding to 
gplOO amino acids 457-466, we identified the gplOO peptide 154-162 as a second 
epitope recognized by TIL 1200. A hundred fold lower concentration of this novel 
gplOO peptide was required for target cell sensitization compared to peptide 457-
466, indicating that the 154-162 peptide is the dominant gplOO epitope for TIL 1200. 
Together with the recently described gplOO 280-288 epitope, three distinct CTL 
epitopes have now been identified in gplOO, all presented in the conctext of HLA-
A2.1. Therefore, gplOO is an attractive target antigen in the development of immuno-
therapeutical protocols against melanoma. 
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Introduction 
CTL that recognize melanoma tumor cells in a Τ cell receptor (TcR) mediated 
and MHC restricted manner have been isolated from tumor bearing patients (for a 
review see (1)). However, the identity of the antigens and epitopes recognized by 
anti-melanoma CTL remains largely unknown. These CTL often display cross-
reactivity with allogeneic HLA-A2.1 matched melanomas, implying that shared 
melanoma antigens are recognized in the context of HLA-A2.1 (2,3). Recently, it has 
been reported that some CTL not only react with melanoma tumor cells, but also with 
normal melanocytes, suggesting recognition of melanocyte differentiation antigens 
(4). 
Using a genetic approach, Boon and colleagues have succeeded in identifying 
a number of antigens recognized by anti-melanoma CTL. Apart from the tumor 
specific MAGE-1 and -3 antigens (5,6), they also identified the melanocyte lineage-
specific tyrosinase protein as a target for melanoma-specific CTL (7). Similarly, we 
identified the gplOO melanocyte specific protein as a target antigen for melanoma 
tumor infiltrating lymphocytes (TIL) (8). Recently, another melanocyte differentiation 
antigen, Melan A/MART-1, was identified as a target for anti-melanoma CTL (9,10). 
Collectively, these findings demonstrate that melanocyte differentiation antigens can 
be immunogenic. 
The gplOO antigen is an intracellular glycoprotein of approximately 100 kD 
and is recognized by mAb NKI-beteb (11). Expression of gplOO is restricted to cells 
of the melanocytic lineage. Recently, we isolated a cDNA clone encoding gplOO 
(12). Characterization of the gplOO cDNA revealed that gplOO is a type I 
transmembrane glycoprotein highly homologous to another melanocyte specific 
protein, Pmell7 (13). Introduction of the gplOO encoding cDNA into gplOO negative 
BLM cells conferred susceptibility to lysis by tumor infiltrating lymphocytes derived 
from a melanoma patient (TIL 1200) (8). Furthermore, short term cultures of HLA-
A2.1+ normal melanocytes were also lysed by TIL 1200, demonstrating that TIL 
1200 recognizes the non-mutated gplOO protein. 
Recently, it has been demonstrated that a naturally processed gplOO peptide 
(amino acids 280-288) that was identified by tandem mass spectroscopy, could direct 
target cell lysis by HLA-A2.1+ restricted anti-melanoma CTL lines (14). We showed 
that TIL 1200 is reactive with the gplOO peptide 457-466 in the context of HLA-
A2.1 (15). Here, we report the identification of a novel HLA-A2.1-presented gplOO 
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peptide, corresponding to amino acids 154-162, as the dominant epitope recognized 
by the oligoclonal TIL 1200 line. 
Material and methods 
Cell Culture. TIL 1200 lymphocytes were isolated from metastatic melanoma 
and were grown as was described previously (3). HLA-A2.1+ melanoma lines BLM and BLM 
gplOO H2.3 were cultured as described previously (8). COS-7 cells were grown in DMEM 
supplemented with 7.5% FCS. TAP-deficient TxB cell hybrid T2 cells (16) were maintained in 
Iscoves medium (Gibco) + 7.5% FCS. 
Peptides. Peptides were synthesized with a free carboxy-terminus either by f-moc 
peptide chemistry using an ABIMED Multiple Synthesizer or by t-boc chemistry on a 
Biosearch SAM2 peptide synthesizer. Peptides were dissolved in DMSO or PBS and stored at 
-20°C. 
DNA Construction and Transfection. Isolation of the gplOO cDNA clone cl has 
been described elsewhere (12). The gplOO cDNA was inserted into expression vectors 
pBJlneo (17), pCMVneo (18) and pSVL (Pharmacia Biotech, Woerden, The Netherlands). 
For the generation of a gplOO cDNA lacking the coding sequences for the peptide 457-466, 
PCR reactions were performed with the following combinations of oligonucleotides: 5'-
CATGGAAGTGACTGTCTACC-3' / 5'-CTGAGCGAATTCGGAACCTGTAATACTT-
TCCG-3' and 5'-CTGAGCGAATTCGTGAAGAGACAAGTCCCCC-3' / 5-TCAC-
AGCATCATATGAGAGTAC-3' using the full length gplOO cDNA as a template. PCR 
products were digested with Eco RI, ligated and served as a template for a nested PCR using 
the following primers: 5'-GCACAGGCCAACTGCAGA-3' / 5-TTCAGTATCTGGTG-
CAGAAC-3'. The Kpn I-Cla I fragment from this PCR product was then exchanged with the 
corresponding fragment in pCMVgplOOneo to generate pCMVgplOODEL454-481neo. GplOO 
cDNA mutants DEL149-661 and DEL454-661 were obtained by deletion of the 1.7 kb Hind III 
and the 0.8 kb Eco RI fragments from pBJlgplOODEL454^181neo respectively. GplOO cDNA 
mutants DEL100-661, DEL194-528 and DEL167-508 were obtained by deletion of the Bgl I-
Sac I, Bam HI-Bgl II and Apa I-Nsi I fragments from pSVLgplOO respectively. 
BLM cells were transfected with 20 μg of pCMVgpl00DEL454-481neo DNA 
according to the calcium phosphate coprecipitation procedure (19) using Calcium phosphate 
Transfection Systems (BRL, Gaithersburg, MD) and were selected with 1 mg/ml G418 
(Gibco, Paisley, Scotland UK). 
COS-7 cells were co-transfected with 5 μg of pBJlHLA-A2.1neo and 5 μg of pBJl or 
pSVL plasmids containing either full length or deleted gplOO cDNAs using the DEAE-
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dextran/chloroquine method (20) (the HLA-A2.1 cDNA was kindly provided by J.J. Neefjes, 
the Netherlands Cancer Institute, Division of Biochemistry, Amsterdam, the Netherlands). 
After 48 hours of transfection COS-7 cells were used as stimulator cells in IFNy release 
experiments. 
Chromium Release Assay. Chromium release assays were performed as described 
previously (8). Briefly, 10^ target cells were incubated with 100 μΟ Na2^'Cr04 (Amersham, 
Bucks, UK) for 1 hour. Various amounts of effector cells were then added to 2.10^ target cells 
in triplicate wells of U bottomed microtiter plates (Costar, Badhoevedorp, The Netherlands) in 
a final volume of 150 μΐ. In peptide recognition assays, target cells were preincubated with 
various amounts of peptide for 1.5 hour at 37 °C in a volume of 50 μΐ prior to the addition of 
effector cells. After 5 hours of incubation part of the supernatant was harvested and its 
radioactive content was measured. 
FNy release assay. 105 TIL 1200 responder cells were incubated together with 5.104 
transiently transfected COS-7 stimulator cells in 300 μΐ medium in the presence of 100 U/ml 
IL-2 in a flat bottom 96 well microtiter plate. After 24 hours of incubation, 100 μΐ of 
supernatant was harvested and was screened for the presence of IFNy using a hlFNy-IRMA 
immunoradiometric assay kit (Medgenix Diagnostics SA, Fleuras, Belgium). 
HLA-A2.1 stabilization on T2 cells. Peptide-induced HLA-A2.1 stabilization on 
T2 cells was performed as described previously (21). Briefly, peptides were diluted from 
DMSO stocks to various concentrations (final DMSO concentration 0.5%) and were incubated 
together with 105 T2 cells for 14 hours at 37°C, 5% COj in serum-free Iscoves medium in a 
volume of 100 μΐ in the presence of 3 μ^ητί human ß2-microglobulin (Sigma, St Louis, MO). 
Stabilization of HLA-A2.1 molecules at the cell surface of T2 cells was analyzed by flow 
cytometry using a FACScan flowcytometer (Becton and Dickinson & Co, Mountain View, 
CA). Anti-HLA-A2 mAb BB7.2 (culture supernatant) (22) was used as a primary reagent. 
FITC conjugated GAM-IgG-F(ab')2 (Zymed, San Francisco, CA) was used for the second 
incubation. 
Results 
TIL 1200 is reactive with more than one peptide derived from gplOO 
To determine the nominal gplOO epitope being recognized by TIL 1200, a number of 
gplOO derived peptides were synthesized according to the HLA-A2.1 binding motifs 
(23-25) and were tested for their ability to sensitize target cells (15). From those, only 
one peptide, corresponding to amino acids 457-466, was able to induce target cell 
lysis by TIL 1200. However, when this peptide was used in chromium release assays 
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(Figure 1), we observed only a low percentage of specific release (20-25 %) 
compared to the lysis we observed (50-70 %) when HLA-A2.1+ melanoma cells 
expressing gplOO were used as target cells. Furthermore, a relatively high 
concentration of peptide (-100 ng/ml) was needed to induce target cell lysis by TIL 
1200. We therefore questioned whether other gplOO derived peptides could be 
recognized by TIL 1200, a TIL line that was found to be oligoclonal when analyzed 
Figure 1. TIL 1200 recognizes the 
gplOO 457-466 peptide. Chromium 
labelled T2 target cells were 
preincubated for l.S hours with 
various amounts of peptide. TIL 
1200 lymphocytes were added at an 
effector to target ratio of 30. After 
5 hours of incubation chromium 
release was measured. Peptide 
gplOO 96-105 is an irrelevant 
gplOO derived peptide that binds to 
HLA-A2.1. 
A putative second gplOO peptide being a candidate for recognition by TIL 
1200, was peptide 280-288. This naturally processed peptide was identified using 
tandem mass spectroscopy and was found to be recognized with high affinity by five 
melanoma-specific CTL lines (14). We tested this peptide for recognition by TIL 1200 
but could not observe any reactivity (data not shown). 
To address the question whether TIL 1200 might recognize another peptide 
derived from gplOO, we constructed a mutant gplOO cDNA. The obtained construct, 
pBJl-gpl00DEL454-481neo, encodes a protein in which the 457-466 peptide is 
absent. We transfected human HLA-A2.1+ gplOO" BLM melanoma cells with pBJl-
gpl00DEL454-481neo DNA. Subsequently, G418 resistant BLM gplOO DEL454-
481 clones were screened for expression of mutated gplOO using m Ab NKI-beteb 
and were tested in chromium release assays using TIL 1200. As shown in Figure 2, 
elimination of the 457-466 epitope did not abolish TIL 1200 reactivity: BLM gplOO 
at the Τ cell receptor (TcR) level (26). 
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DEL454-481 clones were as efficiently lysed as BLM gplOO cells. We therefore 
conclude that the TIL 1200 line recognizes more than one epitope derived from 
gplOO. 
targets: 
>— BLM 
•— BLMgplOOH2.3 
«— BLM gplOO DEL454-481 ПА1 
*— BLMgpl00DEL454-481ID5 
Figure 2. TIL 1200 recognizes more than one epitope derived from gplOO. HLA-A2.1+ BLM 
melanoma cells were used as target cells. BLM gplOO transfectants that do (H2.3) or do not 
express the gplOO 457-466 epitope (DEL 454-481 IIA1/ID5) were recog-nized by TIL 1200. 
GplOO peptide 154-162 is the second gplOO epitope recognized by TIL 
1200 Subsequently, to define the region of the gplOO protein that contains 
the unknown second epitope, a number of different gplOO cDNA deletion mutants 
were generated that all lacked the sequence encoding the 457-466 epitope (Figure 
3). These mutant gplOO cDNAs, cloned into the expression vectors pBJl-neo or 
pSVL, were transfected into COS-7 cells together with an expression vector carrying 
the HLA-A2.1 cDNA. These COS-7 transfectants were then tested for their ability to 
induce IFNy secretion by TIL 1200 upon TcR engagement. 
As shown in Figure 3, TIL 1200 specifically secreted IFNywhen stimulated 
with COS-7 cells transfected with HLA-A2.1 and the full length gplOO cDNA. In 
accordance with the cytotoxicity data (Fig. 2), we again observed TIL 1200 
reactivity against the gplOO DEL454-481 mutant that does not encode the 457-466 
epitope. From the other gplOO deletion mutants, only the DEL100-661 and DEL149-
661 constructs were not recognized, thereby excluding the possibility that TIL 1200 
was reactive with a peptide located N-terminal from amino acid position 148 in the 
gplOO protein. We could also exclude the C-terminal region of the gplOO protein, 
because we observed TIL 1200 reactivity using a mutant construct, DEL454-661, 
encoding the first 453 amino acids of gplOO. The observation that a construct 
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encoding the N-terminal region up to amino acid 166 was able to stimulate TIL 1200 
(DEL 167-508), demonstrated that a presumptive second epitope was localized 
between amino acids 148-166 of the gplOO protein. 
gplOO cDNA constructs 
FL 
DEL 100-661 
DEL 194-528 
DEL 167-508 
DEL 454-481 
DEL 454-661 
DEL 149-661 
IFNy released by TIL 1200 
1 99 
1 193 
1 ¡¡166 
1
 : : 
! ! 
1 148;; 
148-166 
529 
509 
453 482 
453 
661 
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661 
661 
40 60 80 
IFNy (pg/ml) 
Figure 3. TIL 1200 recognizes a second gplOO derived epitope located between amino acids 149 
and 166. GplOO cDNA deletion mutants encoding parts of the gplOO protein were cloned into 
expression vectors and transfected into COS-7 along with the HLA-A2.1 cDNA. (numbers 
indicate amino acids in the gplOO protein, amino acid 1 refers to the methionine in the signal 
peptide) TIL 1200 lymphocytes and transfected COS-7 cells were co-incubated for 24 hours and 
the amount of IFNy in the supernatant was measured using an immunoradiometric assay. 
Several motifs have been described for 9-mer or 10-mer peptides binding to 
HLA-A2.1, that were deduced from naturally processed and synthetic HLA-A2.1 
binding peptides (23-25). When these motifs were applied to the 148-166 region of 
the gplOO protein, no putative HLA-A2.1 binding peptides were found. We therefore 
screened the 148-166 region of the gp 100 protein for peptides that fitted into a less 
strict motif, including threonine residues at position 2. Using such a motif, a number 
of potential HLA-A2.1 binding peptides from the gplOO 148-166 region were 
synthesized. These peptides were loaded onto HLA-A2.1+ T2 cells and tested for 
their ability to induce TIL 1200 mediated target cell lysis (Figure 4). The five peptides 
tested were all able to sensitize T2 cells for lysis by TIL 1200 when applied at a 
concentration of 10 μg/ml. All these peptides contain the 8-mer peptide 
TWGQYWQV, corresponding to gplOO amino acids 155-162. Next, all peptides were 
titrated to evaluate their relative ability to sensitize T2 target cells for lysis by TIL 
1200. Figure 4 shows that the 9-mer peptide KTWGQYWQV elicited 50% of maximal 
specific lysis by TIL 1200 when applied at a concentration of 3 ng/ml, whereas the 
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other peptides had to be applied at higher concentrations. Therefore, the 9-mer 154-
162 peptide most likely is the naturally processed second gplOO epitope that is 
recognized by TIL 1200. 
(£ 100-1 
peptides: 
VWKTWGQYWQV 
KTWGQYWQVL 
KTWGQYWQV 
TWGQYWQVL 
TWGQYWQV 
'-4 -3 -2 -1 0 1 
10 10 10 10 10 10 10 
peptide concentration ^g/ml) 
Figure 4. TIL 1200 predominantly recognizes the gplOO 154-162 epitope. Chro-mium release 
experiments were performed as in figure 1. Five peptides derived from the gplOO 148-166 
region, varying from an 8-mer to an 11-mer, were tested for recognition by TIL 1200. T2 target 
cells were preincubated with various concentrations of peptide and specific lysis was determined 
at an effector to target ratio of 30:1. 
3n 
о 
9 
ε 
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·— INF ma 58-66 
·— HIV pol 510-518 
l— gplOO 154-162 
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<— gp 100 457-466 
Figure 5. Binding of gplOO epitopes to 
HLA-A2.1. T2 cells were incubated with 
various concentrations of the gplOO 154-
162, 280-288 and 457-466 epitopes or with 
two HLA-A2.1 -presentable viral epitopes. 
HLA-A2.1 stabilization at the cell surface 
was determined by flow cytometry using 
mAb BB7.2. The Fluorescense Index is 
expressed as the experimental mean 
fluorescence divided by the mean 
fluorescence that is obtained when T2 cells 
are incubated with an HLA-A2.1 non-
binding peptide, WMAFKERKV. at a 
similar concentration. 
Binding ofgplOO epitopes 154-162, 280-288 and 457-466 to ΗΙΛ-Α2.1. We 
compared the gplOO 155-162 and 457-466 epitopes that are recognized by TIL 
1200, to the aforementioned gplOO 280-288 peptide and two known viral epitopes 
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presented in HLA-A2.1: the influenza matrix 58-66 peptide (27) and the HIV 
polymerase 510-518 peptide (28). We analyzed the HLA-A2.1 binding capacity of 
the different gplOO epitopes by means of an indirect binding assay using the 
processing defective cell line T2 (21). With this assay, we observed similar HLA-A2.1 
stabilization with the gplOO 280-288 epitope and the tested viral epitopes (Figure 5). 
Both the 154-162 and 457-466 gplOO epitopes bind to HLA-A2.1 with a low affinity 
compared to the binding of the gplOO 280-288 epitope and the viral epitopes. From 
these data we conclude that the gplOO epitopes bind to HLA-A2.1 with distinct 
affinities. 
Discussion 
In the present report, we describe the identification of a novel gplOO epitope, 
corresponding to gplOO amino acids 154-162, that is presented to anti-melanoma 
CTL in the context of HLA-A2.1. We demonstrate that the gp 100 reactive TIL 1200 
line, consisting of several TcR specificities (26), recognizes in addition to the gplOO 
457-466 epitope, also the gplOO 154-162 epitope. HLA-A2.1 binding experiments 
revealed that the gplOO 154-162 epitope and the gplOO 457-466 epitope bind with 
relatively low affinity to HLA-A2.1, compared to the recently reported gplOO 280-
288 epitope (14) and HLA-A2.1 restricted viral epitopes. In part, this may be 
explained by the amino acid composition of the gplOO epitopes recognized by TIL 
1200. The lower affinity for HLA-A2.1 of peptide 457-466 may be due to the 
charged residues at positions 3 and 9 (25). Inefficient binding of the gplOO 154-162 
epitope to HLA-A2.1 may be caused by the presence of a threonine residue at the N-
terminal anchor position, since in most HLA-A2.1 binding peptides leucine or 
methionine residues are present at this site. While both peptides bind to HLA-A2.1 
with low affinity, a hundred fold lower concentration of gplOO peptide 154-162 was 
required for the sensitization of T2 target cells for lysis by TIL 1200, when compared 
to gplOO peptide 457-466. Furthermore, a much higher percentage of specific lysis is 
observed when the 154-162 epitope is loaded onto target cells. We therefore 
consider the 154-162 peptide as the dominant gplOO epitope recognized by TIL 
1200. 
It is surprising that in a single patient anti-melanoma CTL have emerged that 
are reactive with two distinct epitopes derived from gplOO, a self antigen. The gplOO 
epitopes are recognized by at least two Τ cell specificities coexisting within the TIL 
1200 line, that display differences in TcR affinity. Τ lymphocytes bearing potential 
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self reactive TcR can emerge in the periphery. They may have escaped from tolerance 
induction because they bear low affinity TcR, whereas potential autoreactive CTL 
bearing high affinity TcR are probably deleted in the thymus (29) or may be tolerized 
in the periphery. The anti-tyrosinase CTL clones described by Wölfel and colleagues 
and the gplOO 457-466 reactive TIL 1200 lymphocytes, exhibiting low peptide / 
MHC affinity, may have emerged from this type of precursor Τ lymphocytes. High 
affinity autoreactive CTL may have escaped tolerance induction, because they have 
not encountered their antigenic peptide in the thymus or in the periphery. It is 
unclear how high or intermediate affinity CTL, like gplOO 280-288 reactive Τ 
lymphocytes (14) or gplOO 154-162 reactive TIL 1200 lymphocytes, exist in the 
periphery as ignorant Τ lymphocytes without causing apparent autoimmune disease 
(30). A possible explanation is that HLA-A2.1 - gplOO 154-162 / 280-288 complexes 
on normal melanocytes may be recognized by activated CTL, but that they are 
incapable of initiating primary immune responses in vivo. Apparently, in the case of 
melanoma, gplOO reactive precursor Τ lymphocytes can be triggered in vivo. This 
may be the result of a higher expression level of the gp 100 antigen in melanoma cells. 
Alternatively, necrosis in melanoma tumors may lead to uptake and presentation of 
gplOO derived peptides to Τ lymphocytes by professional antigen presenting cells. 
Clinical data, indicating that vitiligo (local depigmentation of the skin) is associated 
with improved survival of melanoma patients (31), suggest that these patients benefit 
from an autoimmune response to melanocytes. In addition, reinfusion of TIL 1200 
plus IL-2 in the autologous patient was accompanied by regression of metastatic 
tumor (15). This suggests that the generation of an immune response against the 
gplOO melanocyte differentiation antigen may have anti-tumor effects in vivo. 
Therefore, the gplOO antigen, of which already three distinct HLA-A2.1 presentable 
epitopes have been identified, is an attractive target antigen in the development of 
immuno-therapeutical protocols against melanoma. 
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Summary 
Recently, we cloned the cDNA encoding the melanocyte lineage-specific 
antigen gplOO and demonstrated that gplOO is recognised by three different 
monoclonal antibodies (mAbs) used to diagnose malignant melanoma. In addition, we 
showed that tumour infiltrating lymphocytes (TIL 1200) from a melanoma patient 
specifically reacted with cells transfected with the gplOO cDNA. Molecular 
characterisation of the gplOO cDNA revealed that the gplOO antigen is highly 
homologous, but not identical, to another melanocyte specific protein, pMell7. Here, 
we report that cells transfected with pMell7 cDNA also react with all three mAbs 
used to diagnose malignant melanoma, NKI-beteb, HMB-45 and HMB-50. Moreover, 
pMell7 transfectants are specifically lysed by TILI 200. These data demonstrate that 
antigenic processing of both gplOO and pMell7 give rise to peptides seen by anti-
melanoma CTL and are therefore potential targets for immunotherapy of malignant 
melanoma. 
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Introduction 
Melanoma is a neoplasm that originates from melanocytes, pigment producing 
cells in the skin. Melanoma is a relatively immunogenic tumour, as demonstrated by 
the presence of both cytotoxic Τ lymphocytes (CTL) and antibodies (1,2) in 
melanoma patients that react with melanoma tumour cells. The availability of 
antibodies and CTL with anti-melanoma reactivity allowed the identification of 
several tumour-associated antigens. These include tumour-specific antigens and 
melanocyte differentiation antigens that are expressed by melanoma tumour cells as 
well as by normal melanocytes and retina (3-11). Identification of the antigens 
recognised by anti-tumour CTL is important for understanding the molecular basis of 
tumour recognition by Τ cells and may lead to the development of new 
immunotherapeutical strategies to treat cancer patients. 
Recently, we cloned the cDNA encoding the melanocyte differentiation 
antigen gplOO and demonstrated that its recognised by three different mAbs used to 
diagnose malignant melanoma, NKI-beteb, HMB-50 and HMB-45 (12,13). In 
addition, we demonstrated that gplOO is recognised by a tumour infiltrating Τ cell 
line (TIL 1200) isolated from a melanoma patient (6). Molecular characterisation of 
the cDNA encoding gplOO revealed that its a type I transmembrane glycoprotein of 
641 amino acids highly homologous to another melanocyte specific protein, pMell7 
(13,14). Nucleotide sequence analysis of genomic DNA indicated that the transcripts 
corresponding to gplOO and pMell7 cDNAs originate from a single gene via 
alternative splicing. The difference between gplOO and pMell7 consist of a stretch 
of 7 amino in the carboxy terminal part of pMell7 (position 567, (13)) that is absent 
in gplOO. In all normal and malignant melanocyte cells expressing the gplOO/pMell7 
gene, gplOO and pMell7 mRNAs are expressed simultaneously. 
Here, we demonstrate that pMell7 like gplOO is recognised by all three mAbs 
used to diagnose malignant melanoma and is properly processed and presented to 
anti-melanoma tumour infiltrating lymphocytes. 
Materials and Methods 
Cells and monoclonal antibodies. Culturing of the melanoma cell lines MEWO, 
BLM and of COS-7 cells have been described (12,13). TIL 1200 was generated from a 
metastatic melanoma and cultured with 1000 U/ml IL-2 (Cetus Corp., Emeryville, CA) as 
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described previously (15). NKI-beteb and HMB-50 have been described previously (16,17). 
HMB-45 was purchased from Enzo Biochem. 
Molecular cloning and nucleotide sequence analysis. Using a reverse transcrip-
tase/PCR (GeneAmp kit, Perkin Elmer, the Netherlands) approach with 5' 
ctgcatggagatcttcatcg-3' as the 5' primer and 5'-ttctgtgagcl£caggaaaatcacagcat-3' as the 3' primer 
we isolated the 3' part of pMell7 cDNA from total RNA isolated from the melanoma cell line 
MEWO. The PCR product was used to replace the 3' part of the gplOO cDNA as present in 
pSVLgplOO+ (13) using Bgl II and the newly created Sac I site in the 3' primer (underlined). 
The resulting construct, pSVLpMell7 was sequenced by the dideoxy-nucleotide sequencing 
method using T7 DNA polymerase (Pharmacia, Woerden, The Netherlands). 
pCMVneopMell7 was constructed by cloning the complete pMell7 cDNA from pSVLpMell7 
as a blunt-ended Xba I- Sac I fragment in the blunt-ended Bam HI site of PCMVneo (18). 
Transections and Immunostaining. Transient expression of DNA constructs in 
COS-7 cells was performed using 40 μg/ml lipofectin reagent (BRL, Gaithersburg, MD) and 
7.5 μg DNA. BLM cells were transfected with 20 μg of pCMVneopMell7 DNA using calcium 
phosphate transfection systems (BRL, Gaithersburg, MD) and stable clones were isolated by 
G418 selection (lmg/ml) as previously described (6). Transfected cells were prepared for 
immunofluorescence using FITC conjugated GAM-IgG-F(ab')2 (Zymed, San Francisco, CA) 
as described previously (12) and examined using a confocal laser scanning microscope at 488 
nm (Biorad MRC 600). 
Metabolic labelling and Immunoprecipitations. Immunoprecipitation experiments 
were performed on metabolically labelled (L-[35s]-methionine/cysteine; Amersham) cells as 
described by Vennegoor et al. (16) using either NKI-beteb or HMB-50 covalently linked to 
protein A-CL 4B sepharose beads (Pharmacia, Woerden, The Netherlands). 
Immunoprecipitates were analysed under reducing conditions by SDS-PAGE using 5-17.5% 
gradient gels. The relative molecular weight of the proteins was determined using co-
electrophorised, pre-stained markers (BRL, Gaithersburg, MD)). Gels were treated with 1 M 
sodium salicylate (pH 5.4) prior to autoradiography (Kodak XAR). 
Chromium Release Assay. Chromium release assays were performed as described 
previously (6). Briefly, 10^ target cells were incubated with 100 \iCi Na51Cr04 (Amersham, 
Bucks, UK) for 1 hour. Various amounts of effector cells were then added to 2.\Φ target cells 
in triplicate wells of U bottomed microtiter plates (Costar, Badhoevedorp, The Netherlands) in 
a final volume of 150 μΐ. After 5 hours of incubation part of the supernatant was harvested and 
its radioactive content was measured. 
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Results 
The gpl00/pMell7 gene encodes both gplOO and pMell7 mRNA as a 
consequence of alternative RNA processing. The pMell7 mRNA encodes a stretch 
of 7 amino acids not-encoded by the gplOO mRNA (Figure 1). To investigate the 
immunological properties of pMell7 we constructed a pMell7 cDNA. Using an 
RT/PCR approach we first cloned the 3' part of the pMell7 cDNA encoding the 
carboxy terminal part of pMell7 including the additional 7 amino acids absent in 
gplOO. Nucleotide sequence analysis of the 3' part confirmed the presence of the 
nucleotide sequence encoding the pMell7 specific amino acids. In addition, we 
found pMell7 cDNAs containing either a thymidine (as in the gplOO cDNA (13)) or a 
cytosine at position 1998. This nucleotide change does not result in an amino acid 
substitution. The finding that the same nucleotide difference was found in a gp 100 
cDNA clone isolated from the same cell line, indicates that this particular cell line 
contains two different alleles of the gpl00/pMell7 gene. Subsequently, we created a 
full length pMell7 cDNA by exchanging the 3' part of the gplOO cDNA with the 3' 
partofpMell7cDNA. 
LLTGQEAGL 
ILLTGQEAGL 
GILLTGQEA 
IMPVPGILL 
QLIMPVPGIL 
QLIMPVPGI 
PMEL17 AWSTQLIMPVPGILLTGQEAGLGQVPL 
GP100 AWSTQLIMPGQEAGLGQVPL 
QLIMPGQEA 
LIMPGQEAGL 
IMPGQEAGL 
Figure 1. Peptides unique in pMell7 and gplOO that fit the HLA-A2.1 binding motifs. The 
pMell7 specific amino acids are indicated in bold. 
To investigate whether the difference between gplOO and pMell7 affects 
recognition by the anti-gplOO mAbs NKI-beteb, HMB-45 and HMB-50, we 
transfected the cDNA encoding pMell7 into the gpl00/pMell7 negative melanoma 
cell line BLM. As shown in figure 2, expression of the pMell7 cDNA resulted in 
immunoreactivity with all three mAbs. The typical speckled staining pattern of the 
pMell7 transfectants was identical to that previously observed for gplOO, 
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suggesting that pMell7, like gplOO, localises in melanosomes. Immunoreactivity with 
all three m Abs was also observed when pMell7 cDNA was transiently expressed in 
non-melanocytic COS-7 cells (data not shown). 
Figure 2. MAbs NKI-beteb, HMB-45 and HMB-50 recognise pMell7. BLM cells transfected 
with PSVLpMein were analysed for reactivity with NKI-beteb (1), HMB-45 (2), HMB-50 (3) or 
the secondary antibody (4) respectively. Indirect immunofluorescence (FITC conjugated GAM-
IgG-F(ab')2) was examined by confocal laser scanning microscopy. Magnification 60x. 
We also analysed the pMell7 protein detected by m Abs NKI-beteb or HMB-
50 in COS-7 cells transfected with the pMell7 cDNA using immunoprecipitations 
reactions. As shown in figure 3, NKI-beteb and HMB-50 both specifically detect 
proteins of approximately 100 kD (95-110 kd) in extracts of metabolically labelled 
COS-7 cells transfected with the pMell7 cDNA. The pMell7 protein co-migrates 
with the gplOO protein immunoprecipitated from COS-7 cells transfected with gplOO 
cDNA as well as with the proteins immunoprecipitated from MEWO melanoma cells. 
The slight difference in mobility between transfected COS-7 cells and MEWO 
melanoma cells, that express both gplOO and pMell7 endogenously, has previously 
been shown to be due to differential glycosylation (13). Collectively, these data 
demonstrate that the difference between gplOO and pMell7 does not affect 
recognition by either of the mAbs used to diagnose malignant melanoma, NKI-beteb, 
HMB-50 and HMB-45. The data describing the specificity of these mAbs for cells of 
the melanocytic lineage can therefore be extrapolated to the expresssion of pMell7. 
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Figure 3. The pMell7 protein is 
recognised by NKI-beteb and 
HMB-50 in extracts from 
pSVLpMell? transfected COS-7 
cells. MEWO cells (MEWO) and 
COS-7 cells transfected with either 
pSVL-pMell7 (рМеІП), pSVL-
gplOO (gplOO) or with a construct 
encoding the gplOO cDNA in the 
non-coding orientation (Mock) 
were metabolically labelled and 
subjected to immunoprecipitations 
using NKI-beteb (NKI), HMB-50 
(50) or normal mouse serum 
(NMS) as indicated above each 
lane. Immunoprecipitated proteins 
were analysed under reducing 
conditions by SDS-PAGE (linear 
gradient of 5-17% acrylamide) and 
visualised by auto radiography. The 
position and size (kD) of pre-
stained molecular weight markers 
are indicated. 
-18 
Previously, we showed that gplOO is recognised by tumour infiltrating 
lymphocytes, TIL 1200, isolated from a melanoma patient in an HLA-A2.1 restricted 
manner (6). To investigate whether the pMell7 antigen also gives rise to peptide 
epitopes that gain access to the MHC class I antigen presentation pathway, we 
determined the cytolytic activity of TIL 1200 against HLA-A2.1+ BLM cells 
transfected with the pMell7 cDNA. As demonstrated in figure 4, the pMell7 
transfectants were efficiently lysed by TIL 1200. No specific lysis was observed 
using the parental, untransfected BLM cells or BLM cells transfected with the 
expression vector without an insert (not shown). These data demonstrate that 
peptide epitope(s) recognised by TIL 1200 are properly processed from the pMell7 
protein and presented in the context of HLA-A2.1. Two gplOO derived peptides 
(corresponding to the amino acids at position 154-162 and 457-466) have been 
identified that are recognised by TIL 1200 (19,20). These peptides are located in the 
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Figure 4. Lysis of HLA-A2.1 + 
pMell7 transfectants by TIL 1200. 
BLM cells transfected with 
pCMVneo-pMell7, pCMVneo-
gplOO, the parental BLM cells and 
the gplOO/pMell7 positive Mel 624 
cells were tested for sensitivity to 
lysis by TIL 1200. One 
representative experiment with the 
stable pMell7 transfected clone 
ABl is shown. 
Discussion 
The data described in this report demonstrate that pMell7, like gplOO, is 
recognised by three mAbs frequently used to diagnose melanoma. In addition, we 
demonstrate that cells transfected with pMell7 cDNA are effectively lysed by anti-
melanoma Τ cells. 
Because of the exclusive reactivity of mAbs NKI-beteb, HMB-45 and HMB-
50 with cells of the melanocyte lineage, they are frequently used to diagnose 
malignant melanoma (22). The finding that not only gplOO but also pMell7 reacts 
with these antibodies emphasises the specific expression of both gplOO and pMell7 
in cells of the melanocyte lineage. The identical staining pattern observed with the 
mAbs in gplOO and pMell7 transfectants further indicates that like gplOO, also 
pMell7 is present in melanosomes which is in line with their proposed role in the 
process of pigmentation (14). Whether there exists a functional difference between 
gplOO and pMell7 remains to be determined. 
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1 MDLVLKRCLLHLAVIGALLAVGATKVPRNQDWLGVSRQLRTKAWNRQLYP 
51 EWTEAQRLDCWRGGQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDG 
101 QVIWVNNTIINGSQVWGGQPVYPQETDDACIFPDGGPCPSGSWSQKRSFV 
151 YVWKTWGOYWOVLGGPVSGLSIGTGRAMLGTHTMEVTVYHRRGSRSYVPL 
201 AHSSSAFTITDOVPFSVSVSOLRALDGGNKHFLRNOPLTFALOLHDPSGY 
2 51 LAEADLSYTWDFGDSSGTLISRALWTHTYLEPGPVTAOWLOAAIPLTS 
301 CGSSPVPGTTDGHRPTAEAPNTTAGQVPTTEWGTTPGQAPTAEPSGTTS 
351 VQVPTTEVISTAPVQMPTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGM 
401 TPAEVSIWLSGTTAAQVTTTEWVETTARELPIPEPEGPDASSIMSTESI 
451 TGSLGPLLDGTATLRLVKROVPLDCVLYRYGSFSVTLDIVOGIESAEILO 
501 AVPSGEGDAFELTVSCQGGLPKEACMEISSPGCQPPAQRLCQPVLPSPAC 
551 QLVLHQILKGGSGTYCLNVSLADTNSLAWSTQLIMPVPGILLT GQEAG 
600 LGQVPLIVGILLVLMAWLASLIYRRRLMKQDFSVPQLPHSSSHWLRLPR 
650 IFCSCPIGENSPLLSGQQV 
Figure 5. Amino acid sequence of the pMell7 antigen (including signal peptide) and location of 
the peptide epitopes. The peptide epitopes as recognised in the gplOO antigen are underlined, the 
amino acids uniquely present in pMell7 are in italic capitals. 
The relative immunogenicity of melanoma tumours has long been recognised. 
Both cytotoxic Τ cells and mAbs have been identified that specifically recognise 
melanoma tumour cells. So far, a number of the antigens recognised have been 
characterised in detail. They include the tumour specific proteins, MAGE-1 (3) and 
MAGE-3 (10), that are expressed in different types of tumour cells and in testis. In 
addition, the melanocyte differentiation antigens tyrosinase, gplOO, Melan-A/MART-
1 and gp75 (4,6-9,11) that are expressed in normal and malignant melanocytes as well 
as in retina have been identified as targets for anti-melanoma CTL. Potentially, these 
antigens are targets for specific immunotherapy. 
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TIL 1200 was isolated from a melanoma metastasis and was shown to 
recognise the melanocyte differentiation antigen gplOO. Interestingly, reinfusion of 
in vitro expanded TIL 1200 together with IL-2 in the autologous patient resulted in 
objective tumour regression (8,20). Here we demonstrate that TIL 1200 not only 
recognises the gplOO antigen, but also the pMell7 antigen that is encoded by an 
mRNA species derived from the same gene via alternative splicing. Since we have 
previously shown that melanoma cells express gplOO and pMell7 mRNA 
simultaneously, both proteins contribute to the total amount of immunogenic 
peptides presented in the context of HLA-A2.1 that are recognised by TIL 1200. This 
finding is also consistent with the recent mapping of two peptide epitopes 
(corresponding to the amino acids at position 154-162 and 457-466) recognised by 
TIL 1200 in the common part of gplOO and pMell7 ((8,19) and figure 5). Although it 
has been observed that sequence context can affect processing and/or presentation 
of Τ cell epitopes (23,24), this does not seem to be the case for pMell7 and gplOO. 
The fact that TIL 1200 is an oligoclonal, CD8+ Τ cell line expressing a restricted 
number of Τ cell receptors (21), implies that either one or both these epitopes are 
properly processed from the pMell7 antigen and presented by HLA-A2.1. Attempts 
to further investigate the recognition of the pMell7 epitopes using cloned TIL have 
not been successful. 
Beside TIL 1200, other CTL recognising distinct epitopes encoded by the 
gpl00/pMell7 have recently been characterised (20,25). A total of 5 distinct 
peptides have now been identified (figure 4), all of which are present in both gplOO 
and pMell7, and are presented by the same restriction element, HLA-A2.1. 
Examination of the additional amino acid sequence present in pMell7 revealed that 
6 peptides (including 9 and 10 mers) bearing the HLA-A2.1 binding motif are 
uniquely present in pMell7, whereas 3 peptides are specifically present in gplOO 
(table I). HLA-A2.1 stabilisation experiments revealed that two of the pMell7-
specific peptides listed in table I bind to HLA-A2.1 (A.B.H.B. and G.J.A. unpublished 
observation). When analysing immunoreactivity against the products of the 
gpl00/pMell7 gene, one should therefore include both gplOO and pMell7. 
In conclusion, the data presented in this report demonstrate that pMell7 is 
recognised by three different mAbs used to diagnose melanoma and functions as a 
target for anti-melanoma CTL. 
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Summary 
MHC class I restricted cytotoxic Τ lymphocytes (CTL) specific for antigens 
expressed by malignant cells are an important component of immune responses 
against human cancer. Recently, in melanoma a number of melanocyte differentiation 
antigens have been identified as potential tumor rejection antigens. In the present 
study, we show that applying peptide-loaded dendritic cells, induced by GM-CSF 
and IL-4 from peripheral blood monocytes of healthy donors, we were able to elicit 
melanoma associated antigen specific CTL in vitro. We demonstrate the induction of 
CTL directed against HLA-A2.1 presented epitopes derived from tyrosinase, gplOO 
and Melan A/MART-1. Apart from lysis of peptide-loaded target cells, these CTL 
displayed reactivity with HLA-A2.1+ melanoma tumor cell lines and cultured normal 
melanocytes endogenously expressing the target antigen. These data indicate that 
these CTL recognize naturally processed and presented epitopes and that precursor 
CTL against melanocyte differentiation antigens are present in healthy individuals. 
The ability to generate tumor-specific CTL in vitro using GM-CSF / IL-4 induced 
dendritic cells, illustrates the potential use of this type of antigen presenting cells for 
vaccination protocols in human cancer. 
76 
generation of anti-melanoma CTL using dendritic cells 
Introduction 
CTL that recognize melanoma tumor cells in a Τ cell receptor (TcR) mediated 
and MHC restricted manner have been isolated from tumor bearing patients 
(reviewed in (1)). Using a genetic approach, Boon and colleagues have succeeded in 
identifying a number of antigens recognized by anti-melanoma CTL (2-4). Apart from 
the tumor specific MAGE-1 and -3 antigens (2,4), they also identified the melanocyte 
lineage-specific tyrosinase protein as a target for melanoma-specific CTL (3). 
Similarly, we identified the gp 100 melanocyte specific protein as a target antigen for 
melanoma tumor infiltrating lymphocytes (5). Recently, two other melanocyte 
differentiation antigens, Melan A/MART-1 and gp75, were identified as target 
antigens for anti-melanoma CTL (6-8). 
Cox et al reported that a naturally processed gplOO peptide (amino acids 280-
288), identified by tandem mass spectroscopy, could direct target cell lysis by HLA-
A2.1 restricted anti-melanoma CTL lines (9). We demonstrated that the gplOO 
reactive TIL 1200 line is reactive with two other HLA-A2.1 presented gplOO derived 
epitopes (amino acids 154-162 and 457-466) (10,11). Recently, two novel epitopes 
derived from gplOO were shown to direct target cell lysis by HLA-A2.1 restricted TIL 
(12). Furthermore, a number of peptides derived from the other melanocyte 
differentiation antigens, tyrosinase and Melan A/MART-1, have been identified as 
epitopes for HLA-A2.1 restricted anti melanoma CTL (13,14). 
The array of epitopes derived from antigens commonly expressed in melanoma 
tumors now provide a rationale for initiating multi-target tumor vaccination studies. 
However, succesful activation of CD8+ cytolytic effector lymphocytes with anti­
tumor reactivity is critically dependent on adequate presentation of the epitopes 
involved. Dendritic cells (DC), expressing high levels of MHC class I and II and co-
stimulatory molecules, have been shown to be intimately involved in the generation 
of tumor-specific cellular immunity (15). Recently, a method has been developed to 
generate DC from peripheral blood, by culturing progenitor cells in the presence of 
GM-CSF and IL-4 (16). Thus obtained DC proved very potent stimulator cells as was 
demonstrated by their capacity to induce allogenic and autologous mixed 
lymphocyte reactions (16). Furthermore, these cells are extremely well capable of 
processing and presenting antigen (17). Taken together, these GM-CSF / IL-4 
induced DC are attractive candidates for the induction of anti-tumor immune 
responses. 
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In the present study we investigated whether within the Τ cell repertoire of 
healthy donors precursor Τ lymphocytes are present capable of recognizing HLA-
A2.1 -presented peptides derived from the melanocyte differentiation antigens gplOO, 
tyrosinase and Melan A/MART-1. We demonstrate the in vitro induction of tumor-
reactive CTL using dendritic cells, generated from peripheral blood monocytes after 
culture in the presence of GM-CSF and IL-4, as antigen presenting cells. These 
results illustrate the potential use of this type of antigen presenting cells for 
vaccination protocols of human cancer. 
Materials and methods 
Cell Culture. HLA-A2.1 + melanoma lines BLM and BLM gplOO H2.3 were 
cultured as described previously (5). Melanoma lines Mel 397 (HLA-A2.1") and Mel 624 
(HLA-A2.1+) were a kind gift from Dr. Y. Kawakami (National Cancer Institute, National 
Institutes of Health, Bethesda, USA) and were grown as was reported previously (18). BLM 
and Mel 624 cells were screened for tyrosinase and Melan-A/MART-1 mRNA expression by 
PCR using oligonucleotides 5'-TTGGCAGATTGTCTGTAGCC-3' / 5'-AGGCATTG-
TGCATGCTGCTT-3' and 5'-AGACGAAATGGATACAGAGC-3'/ 5-CATGATTAGTAC-
TGCTAGCG-3', as primer combinations respectively (the tyrosinase specific PCR primer 
combination was a kind gift of Dr. N. Brouwenstijn, University Hospital Leiden, Department 
of Clinical Oncology, Leiden, The Netherlands). COS-7 cells were grown in DMEM (Gibco, 
Paisley, Scotland UK) supplemented with 7.5% FCS (BioWhittaker, Verviers, Belgium). 
TAP-deficient TxB cell hybrid T2 cells (19) were maintained in Iseo ves medium (Gibco, 
Paisley, Scotland UK) + 7.5% FCS. WEHI 164 clone 13 cells (20) were kindly provided by 
Dr. P. Coulie (Ludwig Institute for Cancer Research, Brussels, Belgium) and were grown in 
RPMI 1640 supplemented with 7.5 % FCS, L-glutamine (216 mg/1), L-asparagine (36 mg/1) 
and L-arginine (116 mg/1). Isolation of normal melanocytes from foreskin was performed by 
the method of Eisinger and Marko (21) with modifications as described previously (22). 
Melanocytes from early passages were used in TNF release assays. 
HLA-A2.1+ Lymphocytes. Healthy Caucasian volunteers were phenotyped HLA-
A2.1+ by flow cytometry using mAbs BB7.2 (23) and MA2.1 (24). After signed consent the 
donors underwent leukapheresis and PBMC were isolated by Ficoll/Hypaque density gradient 
centrifugation. The cells were cryopreserved in aliquots of 4 χ 10^ PBMC. 
Peptides. For induction of CTL and chromium-release assays, peptides were 
synthesized with a free carboxy-terminus either by f-moc peptide chemistry using an ABIMED 
Multiple Synthesizer or by t-boc chemistry on a Biosearch SAM2 peptide synthesizer. All 
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peptides were > 90% pure as indicated by analytical HPLC. Peptides were dissolved in DMSO 
and stored at -20°C. 
In vitro CTL induction. Using thawed PBMC, dendritic cells were generated as 
described by Romani et al. (16). PBMC were resuspended at 4 χ 10^ cells/ml in Iscoves 
medium containing 5% FCS and were distributed in 6-well tissue culture plates (Costar, 
Badhoevedorp, The Netherlands) at 3 ml/well. After 2 h of incubation at 37°C, the non­
adherent cells were washed away and 3 ml of Iscoves medium containing 5% FCS 
supplemented with 800 U/ml GM-CSF (Schering-Plough, Amstelveen, The Netherlands) and 
500 U/ml IL-4 (Schering-Plough) was added to the wells. After 5 days of incubation IL-la 
(Hoffman-LaRoche, Nutley, NJ) and IFNy (Boehringer Ingelheim, Alkmaar, The 
Netherlands) were added to the medium at final concentrations of 50 LAF U/ml and 150 U/ml 
respectively, and the cells were transferred to an incubator at 30°C. One day later the APC 
were loaded with peptide according the procedure described by Celis et al. (25), with slight 
modifications. The dendritic cells were collected and resuspended at 5 χ 10^ cells/ml in Iscoves 
medium without serum containing 40 μg/ml peptide and 3 μg/ml human ß2-microglobulin 
(Sigma, St. Louis, MO), and were incubated at 30°C for 4 h. Subsequently, the peptide-
loaded APC were irradiated at 5000 rad, centrifuged and resuspended in Iscoves medium 
containing 5% pooled human AB+ serum. Autologous CD8+ enriched responder Τ 
lymphocytes were prepared by adhering thawed PBMC for 2 h and by subsequent depletion of 
the non-adherent fraction of CD4+ Τ cells using the anti-CD4 mAb RTV-7 (26) and Sheep-anti-
Mouse-IgG coated magnetic beads (Dynal, Oslo, Sweden). The resulting population consisted 
of approximately 60% CD8+ Τ cells and 10% remaining CD4+ Τ cells. At the onset of 
stimulation 2 χ 10^ peptide-loaded DC and 2 χ 10*> responder cells were cocultured per well of 
a 24-well tissue culture plate (Costar, Badhoevedorp, The Netherlands) in 2 ml of Iscoves 
medium containing 5% human serum and 5 ng/ml IL-7 (Genzyme, Cambridge, MA). 
On day 10 and weekly hereafter, the responder populations were restimulated. 
Irradiated PBMC (4 χ lOfywell) were incubated for 2 h in a 24-well plate, non-adherent cells 
were removed and 0.5 ml of serum free Iscoves medium was added per well containing 20 
μg/ml peptide and 2 μ^ητί ß2-microglobuIin. After 2 h of incubation the peptide was removed 
and 10° responder cells were added to the wells in 1 ml of medium. One day later, 1 ml of 
medium was added containing IL-2 (Cetus Corp., Emeryville, CA) and IL-7 at final 
concentrations of 10 U/ml and 5 ng/ml respectively. Responder populations were tested for 
their specificity after at least 4 rounds of restimulation. 
Transection of COS-7 cells. Transfection was performed using the DEAE-
dextran/chloroquine method (27). Briefly, 9 χ 10^ semi-confluent COS-7 cells were 
transfected with 5 μg of pBJlHLA-A2.1neo (11) alone or in combination with 5 μg of 
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pBJlgplOOneo (5). After 48 hours of transfection COS-7 cells were used as stimulator cells in 
TNF release experiments. 
Chromium-release assay. The melanoma tumor cells used as targets were incubated 
for 48 h with 50 U/ml IFNy. Chromium release assays were performed as described 
previously (5). Briefly, 10^ target cells were incubated with 100 цСі Na2^Cr04 (Amersham, 
Bucks, UK) for 1 h. Various amounts of effector cells were then added to 2.10^ target cells in 
triplicate wells of U bottomed microtiter plates (Costar, Badhoevedorp, The Netherlands) in a 
final volume of 150 μΐ. In peptide recognition assays, T2 target cells were preincubated with 
various concentrations of peptide for 90 min at 37 °C in a volume of 100 μΐ prior to the 
addition of effector cells. After 5 h of incubation part of the supernatant was harvested and its 
radioactive content was measured. 
TNF release assay. CTL responder cells (3 χ 10^ ) were incubated with either 3 χ 
1θ4 melanoma tumor cells, 4 χ IO** cultured normal melanocytes or 2 χ 10^ transiently 
transfected COS-7 cells in 100 μΐ of Iscoves medium containing 5% human serum and 5 ng/ml 
BL-7. After 24 h, 50 μΐ of the supernatant was harvested and its TNF content was measured by 
testing its cytolytic effect on WEHI 164 clone 13 cells (20) using a colorimetrie assay as 
described previously (28). 
Results 
Induction of CTL recognizing melanocyte differentiation antigen derived 
epitopes. To asses whether within the Τ cell repertoire of healthy donors 
precursor Τ lymphocytes are present capable of recognizing melanocyte 
differentiation antigen derived epitopes, we initiated in vitro cultures of peptide-
loaded stimulator cells together with autologous responder Τ lymphocytes. As 
stimulator cells we used higly potent dendritic cells. HLA-A2.1+ DC were generated 
using GM-CSF and IL-4 according to the procedure described by Romani et al. (16). 
These cells were loaded with 40 mg/ml of peptide, irradiated and were added to CD8-
enriched Τ cells. The CTL cultures were initiated in the presence of IL-7. As peptides 
we used HLA-A2.1-presented epitopes derived from the melanocyte differentiation 
antigens gplOO (amino acids 280-288, YLEPGPVTA (9)), tyrosinase (amino acids 
369-377, YMNGTMSQV (13)) and Melan A/MART-1 (amino acids 27-35, 
AAGIGILTV (14)). 
At day 10, the responder populations were restimulated with irradiated 
adherent blood mononuclear cells pulsed with the appropriate peptide. After 24 
hours, IL-7 and IL-2 were added to the cultures. Prior to the second restimulation the 
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responder populations were depleted for contaminating CD4+ Τ lymphocytes (30-
50%). The resulting cultures consisted of > 90% CD3+ CD8+ Τ lymphocytes (data 
not shown). 
gplOO CTL tyrosinase CTL Melan A/MART-1 CTL 
• T2 + YLEPGPVTA (gplOO 280-288) 
D T2 + YMNGTMSQV (tyrosinase 369-377) 
• T2 + AAGIGILTV (Melan A/MART-1 27-35) 
Figure 1. Peptide specific reactvity of in vitro induced melanocyte differentiation antigen specific 
CTL cultures. Chromium-labelled HLA-A2.1+ T2 target cells were pre-incubated for 90 min with 
1 mM of the indicated peptides. The different CTL cultures were added at an effector to target 
ratio of 40:1. After S hr of incubation chromium release was measured. 
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Figure 2. Bulk anti-gplOO CTL 
efficiently recognize T2 cells 
loaded with peptide YLEPGPVTA. 
A. Chromium-labelled T2 target 
cells were pre-incubated with 1 mM 
of peptide. The anti-gplOO 280-
288 CTL culture was then added at 
different effector to target ratios. 
After 5 hr of incubation chromium 
release was measured. Peptides: 
· - · , gplOO 2 8 0 - 2 8 8 
YLEPGPVTA; О—O, tyrosinase 
369-377 YMNGTMSQV. B. 
Chromium-labelled T2 target cells 
were pre-incubated with various 
concentrations of gplOO 280-288 
YLEPGPVTA peptide.The anti-
gplOO 280-288 CTL culture was 
then added at an effector to target 
ratio of 15:1. After 5 hr of 
incubation chromium release was 
measured. 
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After two more rounds of restimulation responder cells were tested for 
cytotoxic activity (Fig. 1). All three bulk CTL populations efficiently lysed HLA-
A2.1+ T2 target cells incubated with the relevant peptides, whereas only low 
background lysis was observed in the presence of an irrelevant peptide. CTL 
directed against the gplOO 280-288 epitope were particularly efficient in lysing 
target cells loaded with the YLEPGPVTA peptide (Fig. 2A). Peptide titration showed 
that half-maximal lysis for this CTL culture was obtained at a gp 100 280-288 peptide 
concentration of approximately 500 pM (Fig. 2B). These results demonstrate that 
peptide-speciflc CTL bulk cultures could be obtained with the described induction 
protocol. 
D BLM 
M Mel 624 
gplOO CTL tyrosinase CTL Melan A/MART-1 CTL 
.a 15 
,a io 
I 5 
ΙΛ 
0 
0 10 20 30 
E/T ratio 
Figure 3. Peptide-induced melanocyte differentiation antigen specific CTL cultures specifically 
lyse antigen positive melanoma cells. A. Chromium-labelled HLA-A2.1+BLM and Mel 624 
melanoma cells were used as target cells. BLM cells lack expression of gplOO, tyrosinase and 
Melan A/MART-1. The different CTL cultures were added at an effector to target ratio of 40:1. 
After 5 hr of incubation chromium release was measured. B. The anti-gplOO CTL culture was 
added at different effector to target ratios to chromium labelled BLM (О—O) or BLM gplOO 
H2.3 ( · — · ) target cells. After 5 hr of incubation chromium release was measured. 
Peptide-induced CTL display reactivity with melanocyte differentiation 
antigen expressing cells. To address the question whether the CTL responder 
populations could also recognize endogenously processed and presented antigen, 
we performed chromium-release experiments now using HLA-A2.1+ melanoma cell 
lines BLM and Mel 624 as targets. BLM cells have lost expression of the gplOO 
antigen, both at the protein and at the mRNA level (29). They furthermore lack 
expression of both tyrosinase and Melan A/MART-1 as was assessed by PCR (data 
not shown). In contrast, Mel 624 cells express all three antigens. As shown in figure 
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ЗА, all peptide-induced CTL cultures lysed the antigen expressing Mel 624 cells, 
whereas no lysis was observed against antigen negative BLM cells. These data show 
that the three different CTL cultures induced using peptide-loaded DC, all 
recognized native epitopes derived from gplOO, tyrosinase and Melan A/MART-1 
endogenously processed and presented by HLA-A2.1+ Mel 624 cells. The finding 
that gplOO expressing BLM transfectants were lysed by the anti-gplOO 280-288 
CTL culture confirmed this notion (Fig. 3B), and demonstrated that transfected BLM 
cells are able to process and present antigenic peptides. 
stimulators HLA-A2.1 gplOO 
Mel 397 
Mel 624 + 
BLM + 
BLMgpI0OH2.3 + 
+ 1 
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Figure 4. Recognition of HLA-
A2.1* gplOO* melanoma cells by 
anti-gplOO 280-288 CTL. The anti-
gplOO CTL culture was cocultured 
together with different melanoma 
tumor cells. After 24 h of 
incubation part of the supernatant 
was harvested and its TNF content 
was measured in a bio-assay using 
WEHI 164 clone 13 cells. 
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COS-7 
COS-7A2.1 
COS-7 A2.1gpl00 
5 10 15 20 
TNF release (pg/ml) 
Figure 5. Recognition of COS-7 
cells transfected with HLA-A2.1 
and gplOO cDNA by anti-gplOO 
CTL. Bulk anti-gplOO CTL were 
added to the transfectants and after 
24 h of incubation part of the 
supernatant was harvested and its 
TNF content was measured in a bio-
assay using WEHI 164 clone 13 
cells. As controls, COS-7 cells 
transfected without DNA or with 
HLA-A2.1 cDNA alone were tested. 
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Figure 6. Recognition of HLA-
A2.1+ cultured normal melanocytes 
by anti-gplOO CTL. Bulk anti-
gplOO CTL were added to the 
transfectants and after 24 h of 
incubation part of the supernatant 
was harvested and its TNF content 
was measured in a bio-assay using 
WEHI 164 clone 13 cells. 
Melanocytes from early passages 
were used and HLA-A2.1 
expression was assessed by flow 
cytometry using anti-HLA-A2 
mAbs MA2.1 and BB7.2. 
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In addition, we assayed TNF release by the anti-gplOO CTL to demonstrate 
engagement of gplOO specific Τ cell receptors. Figure 4 clearly demonstrates that 
gplOO 280-288 specific CTL are only triggered to secrete TNF by HLA-A2.1+ 
melanoma tumor cells that express the gplOO antigen. These results confirm the data 
we obtained with the chromium-release assays. To demonstrate that the observed 
TNF production is HLA-A2.1 restricted and gplOO specific, we co-transfected COS-7 
cells with the HLA-A2.1 and the gplOO encoding cDNAs and used these cells to 
stimulate the anti-gplOO CTL (Fig. 5). These double transfectants stimulated the bulk 
anti-gplOO CTL to produce a significant level of TNF, while COS-7 cells transfected 
without DNA or with the HLA-A2.1 encoding plasmid alone failed to stimulate the 
CTL. Therefore, we conclude that the anti-gplOO CTL recognize the gplOO 280-288 
epitope endogenously presented in HLA-A2.1. 
Since gplOO is expressed in all cells of the melanocytic lineage one would 
predict that also normal melanocytes are recognized by the gplOO 280-288 specific 
CTL, as was previously shown for patient derived anti-melanoma CTL (5,30). To 
investigate this, short term cultures of HLA-A2.1"1" and HLA-A2.1" normal 
melanocytes were tested for recognition by the anti-gplOO bulk CTL culture. 
Melanocytes used in this study all expressed the gplOO antigen to a similar extent 
(data not shown). As shown in figure 6, HLA-A2.1+ melanocytes efficiently 
stimulated the anti-gplOO CTL, whereas HLA-A2.1" melanocytes failed to do so. 
Together, these results demonstrate that peptide-induced in vitro bulk CTL cultures 
recognize epitopes endogenously processed and presented by both antigen positive 
HLA-A2.1+ melanoma tumor cells and transfectants as well as by short term cultured 
normal melanocytes. 
Discussion 
In the present report, we demonstrate that HLA-A2.1-restricted CD8+ CTL 
specific for three distinct melanocyte differentiation antigens can be induced from 
peripheral blood lymphocytes of healthy individuals. These CTL were generated in 
vitro using peptide-pulsed dendritic cells induced from adherent peripheral blood 
mononuclear cells using GM-CSF and IL-4. The obtained bulk CTL populations 
directed against gplOO (YLEPGPVTA), tyrosinase (YMNGTMSQV) and Melan 
A/MART-1 (AAGIGILTV) displayed reactivity with HLA-A2.1+ melanoma tumor 
cells expressing these three antigens. These findings confirm and extend 
observations of other investigators who succeeded in generating peptide-specific 
84 
generation of anti-melanoma CTL using dendritic cells 
CTL capable of recognizing endogenously processed antigen using autologous В 
lymphoblast cells as stimulator cells (25,31,32). The amount of peptide needed for 
target cell recognition by the obtained CTL in these studies was approximately 1 nM 
(31,32). Using DC as stimulator cells, we show that gplOO 280-288 specific CTL can 
be induced that require a comparable amount of peptide. 
The presence of CTL in the Τ cell repertoire of healthy donors capable of 
recognizing melanocyte differentiation antigens, indicates that deletion of potential 
auto-antigen reactive CTL precursors has not occured. It may be that these precursor 
Τ lymphocytes have not yet encountered their antigen and exist in the periphery as 
ignorant Τ lymphocytes (33). In this case, the in vitro activation of melanocyte 
differentiation antigen reactive CTL reflects the induction of a primary immune 
response. Alternatively, such lymphocytes may have seen melanocyte derived 
epitopes in vivo resulting in an elevated precursor frequency. In this light the 
described in vitro CTL induction can be regarded as a secondary response. In vivo 
priming of melanocyte antigen specific CTL could be one of the causes of 
melanocyte-destruction as is seen in part of the vitiligo patients. The elevated 
precursor frequency of melanocyte antigen specific CTL might explain results of 
Rivoltini et al. who were able to generate donor derived Melan A/MART-1 specific 
CTL by just pulsing PBMC with peptide whitout applying specialized APC (34). 
Therefore, it remains to be established whether the induced CTL reactivities 
described here are primary immune responses or reflect weak secondary responses. 
So far four melanocyte differentiation antigens have been identified as target 
antigens for anti-melanoma CTL. Adoptive transfer of tumor infiltrating lymphocyte 
populations containing CTL specificities for gplOO, tyrosinase and gp75 resulted in 
objective tumor regression in melanoma patients (8,10,35). This suggests that patients 
may benefit from an immune response against these antigens. Apart from 
occasionally occurring vitiligo, no toxic side effects against normal tissues expressing 
these antigens, like retina and skin, were observed in these patients. The occurrence 
of Τ lymphocytes recognizing melanocyte differentiation antigens within healthy 
donors as demonstrated by our study and by those of others (32,34), indicates that 
the Τ cell repertoire is capable of generating responses against these differentiation 
antigens. Moreover, with these results the two basic requirements for vaccination, 
well characterized target antigens and the presence of precursor Τ lymphocytes 
capable of recognizing the target antigens, have been fulfilled. Therefore, melanocyte 
differentiation antigens are attractive candidates for active immunotherapy in 
melanoma. 
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Summary 
The MHC class I binding-affinity of an epitope is an important parameter 
determining the immunogenicity of the peptide-МНС complex. In order to improve 
the immunogenicity of two epitopes derived from melanocyte lineage-specific 
antigens gplOO and Melan-A/MART-1, we performed amino acid substitutions 
within the epitopes and assayed both HLA-A*0201 -binding and CTL recognition. 
Anchor replacements towards the HLA-A*0201 peptide-binding motif gave rise to 
peptides that bound with higher affinity to HLA-A*0201 compared to wild type. In 
case of the Melan-A/MART-1 27-35 epitope, these anchor replacement analogues 
were inefficient compared to the native epitope in triggering anti-Melan-A/MART-1 
27-35 CTL, demonstrating that anchor residues influence TCR recognition of this 
particular epitope. In contrast, for the gplOO 154-162 epitope, several epitope-
analogues were more efficient in target cell sensitization for lysis by anti-gplOO 154-
162 CTL. These altered gplOO 154-162 epitopes were subsequently tested for their 
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capacity to induce CTL responses in vivo using HLA-A*0201/KD transgenic mice, 
and in vitro using HLA-A*0201+ donor-derived lymphocytes. Interestingly, 
obtained peptide-specific CTL raised against the different gplOO 154-162 epitope-
analogues displayed cross-reactivity with target cells endogenously processing and 
presenting the native epitope. These data demonstrate that altered epitopes can be 
exploited to elicit native epitope-reactive CTL. Usage of epitope-analogues with 
improved immunogenicity may contribute to the development of CTL-epitope based 
vaccines in viral disease and cancer. 
Introduction 
Cytotoxic Τ cells recognize short peptide fragments of 9-11 amino acids in 
length, which are presented in the antigen-binding groove of MHC class I molecules 
(1,2). These peptides are usually derived from intracellular protein pools and associate 
in the lumen of the endoplasmic reticulum with MHC class I heavy chain and β2-
microglobulin molecules, followed by transportation of the МНС-peptide complex to 
the cell surface. Despite the presence of many putative antigenic peptides within the 
same antigen, only a few peptides are selected for recognition by CTL. 
A major parameter determining cell surface presentation of a given peptide is 
the affinity of the peptide for MHC class I molecules. Analysis of HLA-A*0201-
restricted epitopes recognized by anti-viral CTL demonstrated that the majority of 
these peptides bind to HLA-A*0201 with high affinity. Furthermore, immunogenicity 
analysis of motif containing potential epitopes using HLA-A*0201 transgenic mice 
revealed that a threshold MHC class I affinity was required for a peptide in order to 
elicit a CTL response (3,4). In addition to the MHC class I-binding affinity, stability 
of peptide-МНС complexes at the cell surface contributes to the immunogenicity of a 
CTL epitope (5). Consequently, MHC class I binding-affinity and stability of 
peptide-МНС complexes are important criteria in the selection of specific peptide 
determinants for development of CTL-epitope based therapeutic vaccines. 
Recently, a number of antigens have been identified as target antigens for 
anti-melanoma CTL. Using a genetic approach, Boon and colleagues identified the 
tumor specific antigens MAGE-1 and -3 as well as the melanocyte-lineage specific 
antigen tyrosinase (6-8). Similarly, we identified the gplOO melanocyte-specific 
protein as a target antigen for melanoma tumor infiltrating lymphocytes (9). Recently, 
two other melanocyte differentiation antigens, Melan-A/MART-1 and gp75, were 
identified as target antigens for anti-melanoma CTL (10-12). Eight HLA-A*0201 
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restricted epitopes derived from these antigens have now been characterized, 
displaying varying affinities for HLA-A*0201 (13-18). 
In the present study we examined two HLA-A*0201 presented epitopes 
derived from the melanocyte differentiation antigens gplOO and Melan-A/MART-1 
that do not strictly follow the common HLA-A*0201 peptide-binding motifs in more 
detail. In an attempt to improve the immunogenicity of these two epitopes, we 
performed amino acid substitutions within the epitopes to improve HLA-A*0201-
binding affinity. We demonstrate that epitope-analogues allow the induction of 
peptide-specific CTL displaying cross-reactivity with target cells endogenously 
processing and presenting the native epitope. Usage of epitope-analogues with 
improved immunogenicity may contribute to the development of CTL-epitope based 
vaccines in chronic viral disease and cancer. 
Materials and Methods 
Cell Culture. The HLA-A*0201+ melanoma line BLM was cultured as 
described previously (9). TIL 1200 and TIL 1235 lymphocytes and the melanoma lines Mel 
624 and Mel 397 were a kind gift from Dr. Y. Kawakami (National Cancer Institute, National 
Institutes of Health, Bethesda, USA) and were cultured as was reported previously (19). T2 
cells (20) and HLA-A*0201+ В lymphoblastoid J Y cells were maintained in Iscoves medium 
(Gibco, Paisley, Scotland UK) supplemented with 5% FCS (BioWhittaker, Verviers, 
Belgium). Jurkat A*0201/Kb cells (21) expressing the HLA-A*0201/Kb chimeric molecule 
were cultured in Iscoves medium with 5% FCS supplemented with 0.8 mg/ml G418 (Gibco, 
Paisley, Scotland UK). 
HLA-A*0201+ Lymphocytes. Healthy Caucasian volunteers were phenotyped 
HLA-A2 by flow cytometry using mAbs BB7.2 (22) and MA2.1 (23). The donors underwent 
leukapheresis and PBMC were isolated by Ficoll/Hypaque density gradient centrifugation. The 
cells were cryopreserved in aliquots of 4 χ 10^ PBMC. 
Transgenic mice. HLA-A*0201/KD transgenic mice were kindly provided by Dr. 
L. Sherman (Scripps Laboratories, San Diego, USA; through animal distributor Harlan 
Sprague Dawley, Inc., Indianapolis, USA). Mice were held under clean conventional 
conditions. The transgenic mice express the product of the HLA-A*0201/KD chimeric gene in 
which the a3 domain of the heavy chain is replaced by the corresponding murine H-2 KD 
domain while leaving the HLA-A*0201 αϊ and oc2 domains unaffected (24). This allows the 
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murine CD8 molecule on the murine CD8+ Τ lymphocytes to interact with the syngeneic аЗ 
domain of the hybrid MHC class I molecule. 
Peptides. For induction of CTL and chromium-release assays, peptides were 
synthesized with a free carboxy-terminus by Fmoc peptide chemistry using an ABIMED 
multiple synthesizer. All peptides were > 90% pure as indicated by analytical HPLC. Peptides 
were dissolved in DMSO and stored at -20°C. 
Н1Л-АЮ201 upregulation on T2 cells. Peptide-induced HLA-A*0201 up-
regulation on T2 cells was performed as described previously (25). Briefly, peptides were 
diluted from DMSO stocks to various concentrations (final DMSO concentration 0.5%) and 
were incubated together with 10^ T2 cells for 14 hours at 37°C, 5% CO2 in serum-free 
Iscoves medium in a volume of 100 μΐ in the presence of 3 μ^πύ human ß2-microglobulin 
(Sigma, St Louis, MO). Stabilization of HLA-A*0201 molecules at the cell surface of T2 cells 
was analyzed by flow cytometry using anti-HLA-A2 mAb BB7.2 (22). The Fluorescence 
Index is expressed as: (experimental mean fluorescence + background mean fluorescence) - 1 . 
The background mean fluorescence values were obtained by incubating T2 cells with a HLA-
A*0201 non-binding peptide at similar concentrations. 
Competition basedН1А-АЮ201 peptide-binding assay. Peptide-binding to HLA-
A*0201 was analyzed using HLA-A*0201+ JY cells as was described previously (26). 
Briefly, mild-acid treated J Y cells were incubated with 150 nM Fluorescein (FL)-labelled 
reference peptide (FLPSDC(-FL)FPSV) and with several concentrations of competitor peptide 
for 24 hours at 4° in the presence of 1.0 μg/ml ß2-microglobulin (Sigma, St. Louis, MO). 
Subsequently, the cells were washed, fixed with paraformaldehyde and analyzed by flow 
cytometry. The mean-fluorescence (MF) obtained in the absence of competitor peptide was 
regarded as maximal binding and equated to 0%; the MF obtained without reference peptide 
was equated to 100% inhibition. % inhibition of binding was calculated using the formula: (1-
(MF 150 nM reference & competitor peptide - MF no reference peptide) + (MF 150 nM 
reference peptide- MF no reference peptide)) χ 100%. The binding capacity of competitor 
peptides is expressed as the concentration needed to inhibit 50% of binding of the FL-labelled 
reference peptide (IC50). 
Measurement of МНС-peptide complex stability at 37°C. Measurement of MHC-
peptide complex stability was performed as previously described (5). HLA-A*0201+ 
homozygous JY cells were treated with 10~4 M emetine (Sigma, St. Louis, USA) for 1 hour at 
37°C to stop de novo synthesis of MHC class I molecules. The cells were then mild-acid 
treated and subsequently loaded with 200 μΜ of peptide for 1 hour at room temperature. 
Hereafter, the cells were washed twice to remove free peptide and were incubated at 37°C for 
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О, 2, 4 and 6 hours. Subsequently, the cells were stained using mAb BB7.2 (22), fixed with 
paraformaldehyde and analyzed by flow cytometry. 
CTL induction in HIA-A*0201/Kb transgenic mice. Groups of 3 HLA-A*0201 
/К)3 transgenic mice were injected subcutaneously in the base of the tail vein with 100 μg 
peptide emulsified in IFA in the presence of 140 μg of the H-2 I-A^-restricted HBV core 
antigen-derived Τ helper epitope (128-140; sequence TPPAYRPPNAPIL) (27). After 11 days, 
mice were sacrificed and spleen cells (30 χ 10^ cells in 10 ml) were restimulated in vitro with 
peptide-loaded syngeneic irradiated LPS-stimulated В cell lymphoblasts (ratio 4:1). At day 6 of 
culture, the bulk responder populations were tested for specific lytic activity. 
HLA-A*0201+ donor derived CTL induction in vitro. Using thawed PBMC, 
dendritic cells were generated according the procedure of Romani et al. (28) as was described 
previously (29). Before the onset of culture dendritic cells were loaded with 50 μΜ of peptide. 
Autologous CD8+ enriched responder Τ lymphocytes were prepared by adhering thawed 
PBMC for 2 hours and by subsequent partial depletion of the non-adherent fraction of CD4+ Τ 
cells using the anti-CD4 mAb RIV-7 (30) and Sheep-anti-Mouse-IgG coated magnetic beads 
(Dynal, Oslo, Sweden). At the onset of stimulation 2 χ 10^ peptide-loaded DC and 2 χ 10^ 
responder cells were co-cultured per well of a 24-well tissue culture plate (Costar, 
Badhoevedorp, The Netherlands) in 2 ml of Iscoves medium containing 5% pooled human 
AB+ serum, 10^ U/ml IL-6 (Sandoz, Basel, Switzerland) and 5 ng/ml IL-12 (Kindly provided 
by Dr. M. Gately, Hoffmann-La Roche Inc., Nutley, N.J.). 
On day 8 and day 15, the responder populations were restimulated using peptide-pulsed 
dendritic cells as stimulator cells. The cultures were propagated in medium containing IL-2 
(Cetus Corp., Emeryville, CA) and IL-7 (Genzyme, Cambridge, MA) at final concentrations of 
10 U/ml and 5 ng/ml respectively. Weekly hereafter the cultures were restimulated using 
adherent peptide-pulsed PBMC as was described previously (29). Responder populations were 
tested for specific lytic activity after at least 4 rounds of restimulation. 
Chromium-release assay. Chromium release assays were performed as described 
previously (9). Briefly, 10° target cells were incubated with 100 μΟ Na2^Cr04 (Amersham, 
Bucks, UK) for 1 hour. Various amounts of effector cells were then added to the target cells in 
triplicate wells of U bottomed microtiter plates (Costar, Badhoevedorp, The Netherlands) in a 
final volume of 150 μΐ. In peptide recognition assays, target cells were pre-incubated with 
various concentrations of peptide for 30 or 60 min at 37 °C in a volume of 100 μΐ prior to the 
addition of effector cells. After 5 h of incubation part of the supernatant was harvested and its 
radioactive content was measured. The mean percentage specific lysis of triplicate wells was 
calculated using the formula: % specific lysis = ((experimental release - spontaneous release) + 
(maximal release - spontaneous release)) χ 100. 
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Results 
Identification of amino acid residues engaged in HLA-A*0201 binding 
and/or TCR interactions for the Melan-A/MART-1 27-35 and the gplOO 154-162 
epitopes. The Melan-A/MART-1 27-35 and the gplOO 154-162 epitopes have 
been identified using HLA-A*0201 restricted TIL lines derived from metastatic 
melanomas. The Melan-A/MART-1 27-35 epitope was found to be the nominal 
epitope capable of triggering the Melan-A/MART-1 specific TIL 1235 line when 
presented on HLA-A*0201+ target cells (17). Among a panel of peptides ranging 
from 8-mers to 11-mers located around gplOO amino acids 155-161, we identified the 
9-mer 154-162 as the peptide most efficient in sensitizing HLA-A*0201+ target cells 
for lysis by the gplOO reactive TIL 1200 line (16). Both the Melan-A/MART-1 27-35 
9-mer and the gp 100 154-162 9-mer have now been eluted from the cell surface of 
HLA-A*0201+ melanoma cells, and were identified by tandem mass-spectroscopy, 
indicating that they are indeed the nominal epitopes endogenously presented in 
HLA-A*0201 (J. Skipper, personal communication). 
Table I. HLA-A*0201-upreguIation and target cell sensitization of alanine-replacement epitopes. 
Melan A/MART-1 27-35 
YLEPGPVTAC 
AAGIGILTV 
GAGIGILTV 
AGGIGILTV 
AAAIGILTV 
AAGAGILTV 
AAGIAILTV 
AAGIGALTV 
AAGIGIATV 
AAGIGILAV 
AAGIGILTA 
HLA-A*0201 
upregulation3 
50 μΜ 
1.26 
0.20 
0.07. d 
-
-
-
-
0.10 
0.05 
-
25 μΜ 
1.12 
0.11 
0.11 
-
-
-
-
-
0.13 
-
-
target cell lysis 
by TIL 1235° 
-3 
40 
52 
6 
13 
0 
4 
2 
6 
11 
26 
gplOO 154-162 
YLEPGPVTA 
KTWGQYWQV 
ATWGQYWQV 
KAWGQYWQV 
KTAGQYWQV 
KTWAQYWQV 
KTWGAYWQV 
KTWGQAWOV 
KTWGQYAQV 
KTWGQYWAV 
KTWGQYWQA 
HLA-ATJ201 
upregulation 
50 μΜ 
1.06 
0.94 
0.57 
0.17 
0.45 
0.59 
0.42 
0.31 
0.72 
0.08 
25 μΜ 
0.40 
0.42 
0.20 
-
0.13 
0.25 
0.15 
0.14 
0.35 
-
target cell lysis 
by TIL 1200 
3 
67 
75 
64 
58 
63 
9 
7 
-2 
73 
76 
aHLA-A2.1-upregulation was analyzed using the processing-defective T2 cell line at the indicated peptide 
concentrations. Numbers indicate Fluorescence Index: (expenmental mean fluorescence + background mean 
fluorescence) - 1 . 
D
 Numbers indicate % specific lysis by the relevant TIL lines at an E:T ratio of 20:1. Chromium-labelled T2 target cells 
were preincubated for 90 mm with 1 μΜ of peptide. Chromium release was measured after 5 hours of incubation. 
cgp100 280-288. 
dNo detectable HLA-A*0201 upregulation could be observed. 
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To identify amino acid residues in both epitopes engaged in HLA-A*0201 
binding and/or TCR interactions, epitope-analogues were synthesized in which the 
native amino acid was replaced by an alanine residue. In case alanine residues were 
present in the wild type epitope, they were substituted for the amino acid glycine. 
The substituted peptides were assayed for binding to HLA-A*0201 by means of an 
indirect binding assay using the processing defective cell line T2 (25). 
Melan A/MART-1 27-35 gplOO 154-162 
S 50 £ 80 
1 
10 10 10 10 
peptide concentration (uM) 
peptides: 
- · — AAGIGILTV 
10 10 10 10 10 
peptide concentration (μΜ) 
peptides: 
— · — KTWGQYWQV 
GAGIGILTV 
AAGIGILTA 
— O — ATWGQYWQV 
—Ш— KAWGQYWQV 
— • — KTAGQYWQV 
— * — KTWAQYWQV 
—& — KTWGQYWAV 
'— KTWGQYWQA 
Figure 1. Target cell sensitization of alanine-replacement epitopes. (A) Chromium-labelled T2 
target cells were pre-incubated for 1 hr. with various amounts of the indicated alanine-substituted 
epitope-analogues. Melan- A/M ART-1 27-35 reactive TIL 1235 lymphocytes were added at an 
effector to target ratio of 20. (B) Target cell sensitization of alanine-substituted gplOO 154-162 
analogues was analyzed using gplOO-reactive TIL 1200 lymphocytes at an effector to target ratio 
of 20. 
All substitutions in the Melan-A/M ART-1 epitope resulted in a nearly complete loss 
in the capability to stabilize HLA-A*0201 molecules at the cell surface of T2 cells 
(Table I). When the Melan-A/M ART-1 27-35 analogues were used at micromolar 
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concentrations to sensitize HLA-A*0201+ target cells for lysis by Melan-A/MART-l -
specific CTL, we observed a decrease in target cell lysis for the alanine replacements 
at positions 4 to 7 of the epitope (Table I). In addition, the glycine substitution at 
position 2 resulted in decreased CTL reactivity. The amino acids at these positions in 
the Melan-A/MART-l 27-35 epitope are therefore most likely involved in TCR 
interactions. 
In case of the gplOO 154-162 epitope decreased HLA-A*0201 affinity of 
epitope-analogues was only observed for the alanine substitutions at position 3 and 
9 (Table I). With respect to Τ cell recognition, alanine substitutions at positions 5, 6 
and 7 of the epitope were not allowed, indicating that amino acids at these positions 
are critical contact residues within this epitope for the TCR. 
Subsequently, the epitope-analogues that induced reactivity at micromolar 
concentrations, were titrated to evaluate their relative ability to sensitize T2 target 
cells for lysis by the relevant CTL (Figure 1). In all cases the epitope-analogues were 
similar or inferior compared to the wild type epitope in their sensitizing capacity, 
except for the alanine substitution at position 8 of the gplOO 154-162 epitope. 
Surprisingly, this peptide was able to induce target cell lysis by gplOO-reactive CTL 
even at a tenfold lower concentration. 
N-terminal anchor residue replacements in both the gplOO 154-162 and the 
Melan-A/MART-l 27-35 epitopes result in improved affinity for HLA-A*0201. 
Since both the Melan-A/MART-l 27-35 and the gplOO 154-162 epitopes 
have non-conventional N-terminal anchoring residues, we replaced these residues for 
the common HLA-A*0201 anchoring residues V, L, I or M (31). Subsequently, we 
tested these peptides for HLA-A*0201 binding and their ability to sensitize target 
cells for lysis by the relevant CTL. Apart from the methionine substitution, all anchor 
residue replacements in the Melan-A/MART-l epitope resulted in significantly 
improved binding to HLA-A*0201 (Table II). HLA-A*0201+ target cells loaded with 
these peptides at a concentration of 1 μΜ were recognized by the Melan-A/MART-l 
reactive CTL, except for the methionine substituted epitope (Table II). Although this 
peptide did bind to HLA-A*0201 at a level comparable to the wild type epitope, it 
failed to induce CTL reactivity. Titration experiments using the Melan-A/MART-l 
anchor replacement peptides demonstrated that these epitope-analogues were 
inferior to wild type in sensitizing target cells for lysis by TIL 1235 (Figure 2). 
Using the T2 assay all gp 100 154-162 anchor replacement peptides except the 
methionine substituted epitope showed HLA-A*0201 binding comparable to the 
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T a b l e I I . H L A - * A 0 2 0 1 - u p r e g u l a t i o n and 
replacement epitopes 
Melan A/MART-1 27-35 
YLEPGPVTAC 
AAGIGILTV 
AVGIGILTV 
ALGIGILTV 
AMGIGILTV 
A l GIGI LTV 
HLA-A"0201a 
upregulation 
50 uM 
1.26 
0.20 
0.62 
1.21 
0.18 
0.58 
25 μΜ 
1.12 
0.11 
0.36 
0.93 
0.05 
0.29 
target c e l l sensi t izat ion o f N - t e r m i n a l anchor-
target cell lysis 
by TIL 1235 b 
-1 
40 
27 
16 
6 
27 
gpW0154-162 
YLEPGPVTA 
KTWGQYWQV 
KVWGQYWQV 
KLWGQYWQV 
KMWGQYWQV 
Kl WGQYWQV 
HLA-A'0201 
up regulation 
50 μΜ 
1.06 
1.13 
1.19 
0.73 
1.00 
25 μΜ 
0.40 
0.57 
0.55 
0.28 
0.43 
target cell lysis 
by TIL 1200 
3 
67 
69 
65 
57 
68 
aHLA-A2.1-upregulation was analyzed using the processing-defective T2 cell line at the indicated peptide 
concentrations. Numbers indicate Fluorescence Index: (experimental mean fluorescence + background mean 
fluorescence) - 1. 
b
 Numbers indicate % specific lysis by the relevant TIL hnes at an E:T ratio of 20:1. Chromium-labelled T2 target cells 
were preincubated for 90 mm with 1 uM of peptide. Chromium release was measured after 5 hours of incubation. 
c g p l 00 280-288. 
Melan A/MART-127-35 gplOO 154-162 
10" 10" 10 
peptide concentration (μΜ) 
10 10 10 
peptide concentration (μΜ) 
peptides: 
- · — AAGIGILTV 
- o — AVGIGILTV 
-»— ALGIGILTV 
-o— AIGIGILTV 
peptides: 
- · — KTWGQYWQV 
-O— KVWGQYWQV 
-•— KLWGQYWQV 
-О— KMWGQYWQV 
- ± — KTWGQYWQV 
Figure 2. Target cell sensitization of N-terminal anchor-replacement epitopes. Chromium release 
experiments were performed as in figure 1. (A) Melan-A/M ART-1 27-35 reactive TIL 1235 
lymphocytes were used to assay target cell sensitization by the Melan-A/M ART-1 27-35 
analogues. (B) GplOO 154-162 reactive TIL 1200 lymphocytes were used to assay target cell 
sensitization by the gplOO 154-162-analogues. 
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wild type epitope (Table II). Interestingly, these peptides were recognized by TIL 
1200 when loaded on target cells at tenfold lower concentrations compared to the 
wild type peptide (Figure 2), while the methionine substituted peptide showed no 
difference. These findings demonstrate that amino acid substitutions within the 
native epitope can result in improved Τ cell recognition. 
Improved target cell sensitization by gplOO 154-162 epitope analogues 
correlates with increased affinity for HLA-A*0201. To assess whether the 
augmented CTL recognition of the substituted gplOO 154-162 epitopes could be 
attributed to improved HLA-A*0201 affinity, we again tested the HLA-A*0201 
binding capacity of these peptides now using a more sensitive cell-bound HLA-
A*0201 binding assay based on competition of a labelled reference peptide with the 
peptides of interest (26). HLA-A*0201 binding-affinities obtained with this assay 
demonstrated that all peptides that were able to sensitize target cells for lysis by TIL 
1200 at tenfold lower concentrations compared to wild type, also bound with higher 
affinity to HLA-A*0201 (Table Ш). 
Table HI. HLA-A*0201 binding and complex stability of gplOO 154-162 epitope-analogues 
peptide 
FLPSDFFPSV0 
KTWGQYWQV 
KTWGQYWAV 
KVWGQYWO/ 
KLWGQYWCW 
KIWGQYWCW 
Affinity 
ICso OiM)' 
0.5 
1.4 
0.5 
0.8 
0.4 
0.6 
Stability 
(ОТ«,)" 
> 4 h r 
> 4 h r 
> 4 h r 
> 4 h r 
> 4 h r 
> 4 h r 
aESnding of peptides to HLA-A*0201 was analyzed in a competition assay at 4°C using mild acid treated 
HA-A'0201 +B-LCL. The binding capacity ol the peptides is shown as the concentration of peptide 
needed to inhibit 50% ol binding of the fluorescein labelled reference peptide. 
bThe dissociation rate of HLA-A"0 201 -peptide complexes was measured using emetine pretreated HLA-
ΑΌ201 +B-LCL After mild acid treatment, empty cell surface HLA-A'0201 molecules were loaded with 
peptide at room temperature and B-LCLwere then put at 37°C. The decay of cell surface HLA-A*0 201 
molecules was analyzed by flow cytometry. The dissociation rate is depicted as the time required for 
50% of Ih e МНС class l-pept ide complexes to decay at 37°С 
CHLA-A*0201 restricted HBV core 18-27 antigen, unlabelled reference peptide. 
In addition to the N-terminal anchor substitutions, replacement of a polar residue for 
a hydrophobic residue adjacent to the C-terminal anchoring position also resulted in 
an epitope-analogue with improved HLA-A*0201 affinity (KTWGQYWAV), 
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apparently without affecting TCR recognition. Measurement of MHC class I-peptide 
complex dissociation rates demonstrated that the epitope-analogues tested are at 
least equally stable when compared to wild type (Table III). All peptides tested 
showed a DT50 (the time required for 50% of the complexes to decay) longer than 4 
hours. Previously, it was shown that peptides with DT50 values of >3 hours were 
immunogenic in HLA-A*0201/KD transgenic mice (5). Taken together, these data 
indicate that the gplOO 154-162 epitope-analogues may have similar or increased 
immunogenicity compared to wild type gplOO 154-162. 
KTWGQYWAV 
50 75 100 
E/Tralio 
Responding mice 
gplOO 154-162 wild type 2/3 
KTWGQYWAV 
KY.WGQYWQV 
KLWGQYWQV 
KIWGQYWQV 
no peptide 
wild type 
analogue 
3/3 
3/3 
2/3 
3/3 
# 45 KIWGQYWQV 
25 50 75 100 
E/Tratio 
Figure 3. Immunogenicity of gplOO 154-162 epitope-analogues in HLA-A*0201/Kb transgenic 
mice. Bulk CTL obtained from immunized mice were tested for lytic activity using chromium 
labelled Jurkat A2/Kb target cells that were preincubated with no peptide, 10μΜ wild type gplOO 
154-162 or 10μΜ of the epitope-analogue used to immunize the mice. For each peptide the 
mean specific lysis of bulk CTL of the responding mice is shown. Standard deviations never 
exceeded 15% of the mean value. One representative experiment out of two is shown. 
Immunogenicity of gplOO 154-162 epitope-analogues in HLA-A*0201/K" 
transgenic mice. In order to determine the in vivo immunogenicity of the gplOO 
154-162 epitope-analogues of which the MHC class I binding-affinity and 
dissociation rate was measured, HLA-A*0201/KD transgenic mice were vaccinated 
with the gplOO 154-162 wild type epitope, with the epitope-analogues 
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KTWGQYWAV, KVWGQYWQV, KLWGQYWQV or KIWGQYWQV, or with a 
control peptide (HBVcore 18-27; FLPSDDFPSV). The generation of these transgenic 
mice (24) and their use to analyze in vivo immunogenicity have been described 
previously (3,4). As shown in figure 3, the gplOO 154-162 epitope-analogues 
KTWGQYWAV, KVWGQYWQV, and KLWGQYWQV, very efficiently induced a 
CTL response. To a lesser extent also the epitope-analogue KIWGQYWQV and the 
wild type gplOO 154-162 were able to elicit a CTL response. Bulk CTL derived from 
mice vaccinated with the gplOO 154-162 epitope-analogues specifically lysed Jurkat 
A*0201/Kb cells loaded with both the peptide used for vaccination and the wild 
type epitope. Interestingly, CTL bulk cultures raised against the epitope-analogues 
all recognized target cells pulsed with the wild type epitope equally well or better 
compared to target cells pulsed with epitope-analogues used for vaccination. Thus, 
all gplOO 154-162 epitope-analogues tested were immunogenic in HLA-A*0201/Kb 
transgenic mice, and elicited CTL displaying cross-reactivity with the native gplOO 
154-162 epitope. 
In vitro induction of gplOO 154-162 epitope-analogue specific human CTL 
displaying cross-reactivity with endogenously HLA-A*0201 presented wild type 
gplOO 154-162. Next we perfromed in vitro CTL induction assays to assess 
whether within the Τ cell repertoire of HLA-A*0201+ healthy donors precursor Τ 
lymphocytes were present capable of recognizing gplOO 154-162 epitope-
analogues. In order to achieve this, we initiated cultures of peptide-loaded dendritic 
cells together with autologous responder Τ lymphocytes as described previously 
(29). After several rounds of restimulation, responder Τ cells were tested for cytotoxic 
activity (Figure 4). All bulk CTL populations raised against the gplOO 154-162 
epitope-analogues, KTWGQYWAV, KVWGQYWQV, KLWGQYWQV and 
KIWGQYWQV, efficiently lysed HLA-A*0201+ T2 target cells incubated with the 
peptides used for CTL induction. Only low background lysis was observed in the 
presence of an irrelevant peptide. In addition, these gplOO 154-162 epitope-analogue 
reactive CTL efficiently lysed T2 target cells incubated with wild type gplOO 154-
162. 
To address the question whether these CTL responder populations could also 
recognize endogenously processed and presented wild type epitope, we performed 
chromium-release experiments using HLA-A*0201+ melanoma cell lines BLM and 
Mel 624 as targets. BLM cells have lost expression of the gplOO antigen, both at the 
protein and at the mRNA level (32). As shown in figure 5, all peptide-induced CTL 
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g, 100 
J. 80 
υ 
¡S 60 
8. 40 
20 
0 
KTWGQYWQV # 
IdL 
gplOO 154-162 CTL 
KTWGQYWAV 
I I irrelevant peptide 
H wild type 
§3 analogue 
gplOO 154-162 Q>ACTL 
KYWGQYWQV KJLWGQYWQV g, 100 -ι KIWGQYWQV 
t 80-
gplOO 154-162 T>VCTL gplOO 154-162 T>LCTL gplOO 154-162 T>ICTL 
Figure 4. Peptide specific reactivity of in vitro induced epitope-analogue specific CTL cultures. 
Chromium-labelled HLA-A*0201 + T2 target cells were pre-incubated with 10 μΜ of an 
irrelevant HLA-A*0201-binding peptide, ΙΟμΜ wild type gplOO 154-162 or ΙΟμΜ of the 
epitope-analogue used for CTL induction. The different CTL cultures were added at an effector 
to target ratio of 20:1. One representative experiment out of two is shown. 
cultures lysed the antigen expressing Mel 624 cells, whereas no or background lysis 
was observed against antigen negative BLM cells. TNF release by the anti-gplOO 
154-162 analogue CTL further demonstrated the reactivity of these CTL with 
endogenously presented wild type gplOO 154-162 (data not shown). These data 
show that the four different CTL cultures induced using gplOO 154-162 epitope-
analogue loaded dendritic cells, all recognized the native gplOO 154-162 epitope 
endogenously processed and presented by HLA-A*0201+ Mel 624 cells. 
Discussion 
Since MHC class I-affinity and peptide-МНС complex-stability are important 
parameters determining the immunogenicity of an MHC class I presented epitope, we 
explored the possibility to improve the capacity of two melanocyte differentiation 
antigen-derived epitopes to bind to HLA-A*0201 without affecting interactions with 
the TCR. Detailed analysis of the Melan-A/MART-1 27-35 and gplOO 154-162 
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g 60 -ι KTWGQYWQV ë M l KTWGQYWAV 
D BLM gplOO-
• Mel 624 gpl00+ 
gplOO 154-162 CTL gp 100 154-162 Q>A CTL 
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I 50-
a 40 • 
I 3 0 
20 
10 
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MI 
20 
10 
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І 50 
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is 
l 30 
(Λ 
20 
10 
0 
KIWGQYWQV 
gplOO 154-162 T>V CTL gplOO 154-162 T>L CTL gplOO 154-162 T>I CTL 
Figure 5. Epitope-analogue induced CTL cultures specifically lyse melanoma cells endogenously 
presenting the wild type epitope. Chromium-labelled HLA-A2.1+BLM and Mel 624 melanoma 
cells were used as target cells. BLM cells lack expression of gplOO. The different CTL cultures 
were added at an effector to target ratio of 20:1. One representative experiment out of two is 
shown. 
epitopes using alanine substitutions revealed that amino acids at positions 4 to 7 
(Melan-A/MART-1 27-35) or 5 to 7 (gplOO 154-162) are critical residues for TCR 
recognition. These data are in line with X-ray crystallography studies of the HLA-
A*0201 molecule (33,34), implying a role for the more permissive residues at position 
4 and 5 of the peptide oriented towards the outside of the MHC molecule, as 
prominent TCR contact sites. Our data confirm and extend these findings and 
demonstrate that for HLA-A*0201 the amino acids at positions 6 and 7 of the Melan-
A/MART-1 27-35 and gplOO 154-162 epitopes do not only interact with secondary 
pockets in the MHC peptide-binding cleft, but that they are also critical residues for 
TCR interaction (35,36). 
Surprisingly, the alanine substitution at position 8 in the gplOO 154-162 
epitope, KTWGQYWAV, resulted in a peptide that displayed increased HLA-A*0201 
affinity. Moreover, this epitope-analogue was recognized by gplOO-reactive CTL at 
tenfold lower concentrations compared to the native epitope. These data 
demonstrate that amino acid substitutions at a non-anchor position can result in 
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increased МНС class I affinity and Τ cell recognition. Previously, this was shown f 
the HLA-A*0201 -restricted HIV-1 reverse transcriptase 476-484 epitope, in whii 
substitutions at the first position of the peptide resulted in an increased stability 
the peptide-МНС complex at the cell surface (37). 
By N-terminal anchor replacements with V, L, M or I towards the HL· 
A*0201 binding-motifs we set out to identify epitope-analogues for both epitope 
with improved affinity for HLA-A*0201 that were still recognized by wild ty] 
epitope-reactive CTL. For the Melan-A/MART-1 epitope, epitope-analogues we 
obtained with comparable (M) or improved (V, L and I) affinity for HLA-A*020 
However, all N-terminal anchor replacements resulted in decreased Τ cell reactivit 
Apparently, in case of this epitope, the N-terminal anchoring residue affects tl 
positioning of the side chains in the centre of the peptide, thereby abrogating TC 
interactions. Recently, a similar observation has been described involving an HL/ 
B*3501 restricted epitope of the influenza A matrix protein (38). Substitution of 
serine residue at position 2 of the peptide for the more common HLA-B*3501 Î 
terminal anchor proline, considerably enhanced binding to HLA-B*3501, but tl 
epitope-analogue was not recognized by CTL reactive with the native epitop 
Moreover, this peptide behaved as a peptide-antagonist as was demonstrated for 
cell recognition of both MHC class II and class I-presented peptides (38-41). The! 
findings illustrate that anchor residue substitutions not only affect MHC class 
binding, but in some cases they may also result in a conformational change of tl 
peptide-МНС complex, leading to an altered interaction with the TCR. 
In case of the gp 100 154-162 epitope we obtained, in addition to the alanii 
substituted analogue KTWGQYWAV, three anchor substituted epitope-analogui 
KVWGQYWQV, KLWGQYWQV, and KIWGQYWQV, with improved HLA-A*020 
affinity that were recognized by anti-gplOO CTL at tenfold lower concentrado! 
compared to the wild type epitope. In vivo immunization experiments using HL/ 
А*0201/КЬ transgenic mice demonstrated that these epitope-analogues wei 
immunogenic, resulting in the induction of murine CTL reactive with both tl 
epitope-analogues and the native epitope. The immunogenicity of the epitopi 
analogues was expected since the peptide-МНС complex stability of both tl 
epitope-analogues and the native epitope was comparably high. Therefore, οι 
results confirm previous data demonstrating that peptides with low MHC class 
peptide complex dissociation rates can effectively induce CTL responses (5). 
In vitro CTL induction experiments using donor derived PBL demonstrate 
that epitope-analogue specific CTL could be obtained displaying cross-reactivi 
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with tumor cells endogenously presenting the wild type epitope. In addition to Τ 
lymphocytes reactive with the wild type epitope, the Τ cell repertoire of healthy 
donors apparently also contains Τ cells reactive with the gplOO 154-162 epitope-
analogues. Analysis of TCR usage of cloned CTL reactive with the different gplOO 
154-162 epitope-analogues and with wild type gplOO 154-162 will be informative of 
the spectrum of the Τ cell repertoire that can be used to induce CTL reactivity 
towards the wild type epitope. With respect to immunotherapy of cancer, activation 
of multiple specificities in the Τ cell repertoire against an antigenic tumor epitope 
using epitope-analogues may increase the possibility of a patient to mount a 
successful anti-tumor response upon immunization. 
In summary, we describe here the identification of epitope-analogues of the 
gplOO 154-162 epitope with improved immunogenicity, that were obtained by amino 
acid substitutions in both anchor and non-anchor positions in the native epitope. 
Employment of 'improved' epitopes in immunotherapy protocols may increase the 
amount of peptide-МНС complexes at the cell surface of antigen presenting cells in 
vivo, and may result in enhanced priming of antigen-specific CTL. Apart from their 
potential in cancer immunotherapy, usage of epitope-analogues with improved 
immunogenicity may contribute to the development of CTL-epitope based vaccines 
in chronic viral disease. 
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Discussion and perspective 
The identification of antigens on human melanoma cells that can be 
recognized by CTL initiated a new era in the treatment of human cancer by 
immunotherapy. These new antigens can be employed in immunotherapeutical 
protocols that may specifically target the cellular immune system towards the patients 
tumors, resulting in induction of anti-tumor CTL responses in patients. Several 
procedures are now being proposed for Τ cell-mediated immune intervention of 
cancer. However, a number of hurdles still have to be taken before therapeutic 
successes can be achieved. This chapter discusses the results that are described in 
this thesis and their implications for the development of anti-melanoma vaccines. 
Furthermore, a number of prerequisites and variables affecting the outcome of 
antigen-targeted immunotherapy protocols will be discussed. 
gplOO as a target for anti-melanoma CTL 
The observed cross-reactivity of some anti-melanoma CTL with MHC class I-
matched cultured normal melanocytes implied the recognition of antigens that were 
shared between melanoma tumor cells and normal melanocytes (1). With this in mind, 
we followed a reverse approach to the identification melanoma-associated CTL 
target antigens. We focused on a well defined melanocyte lineage-specific antigen, 
the gplOO antigen, and searched for anti-melanoma CTL that could recognize this 
antigen. Using gplOO transfectants we were able to identify gplOO as the target 
antigen for a TIL-derived CTL line (chapter 2). Lysis of HLA-A*0201+ normal 
melanocytes by this TIL line demonstrated that non-mutated peptides derived from 
the self-antigen gplOO were recognized. The gplOO antigen was, in addition to the 
tyrosinase antigen (2), the second melanocyte differentiation antigen identified as a 
CTL target antigen. This finding extended the notion that tumor-associated self-
antigens are potentially immunogenic. This group of shared melanoma antigens was 
enlarged with the identification of the Melan A/MART-1 and gp75 antigens as 
targets for anti-melanoma CTL (3-5). 
In chapter 3 we demonstrate that the oligoclonal TIL 1200 line recognizes 
two peptides derived from gplOO presented in the context of HLA-A*0201. Apart 
from a 10-mer peptide located at position 457-466 in the gplOO protein, we identified 
another epitope located at position 154-162 that induced TIL 1200 reactivity. 
Recognition of gplOO by the TIL 1200 line was not a single observation. Until now 
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several patient derived TIL lines, peripheral blood originated CTL lines and clones 
have been described that recognize this antigen (6-8) (and H. Zerour, personal 
communication). In addition to the two epitopes recognized by the TIL 1200 line, 
three other HLA-A*0201 presented gplOO derived epitopes have been identified 
(6,7). The multiplicity of antigenic determinants in gplOO together with the relatively 
frequent observation of gplOO reactive CTL in patients, may make gplOO an antigen 
of choice for anti-melanoma vaccination protocols. The gplOO antigen may be of 
particular interest, since adoptive transfer of four gplOO-reactive TIL lines, but not of 
six other TIL, resulted in tumor regression in the autologous patients (7). 
Since gplOO and Pmell7 are highly homologous and simultaneously 
expressed in all malignant and normal melanocyte cells analyzed, we investigated 
whether both proteins had similar properties regarding their immunogenicity. In 
chapter 4 we describe that cells transfected with the pMell7 encoding cDNA react 
with all three anti-gplOO mAbs; NKI-beteb, HMB-45 and HMB-50. Furthermore, we 
showed that pMell7 transfectants are specifically lysed by TIL 1200, demonstrating 
that antigenic processing of both gplOO and pMell7 gave rise to peptides 
recognized by anti-melanoma CTL. Therefore, both gplOO and Pmell7 are potential 
targets for immunotherapy of malignant melanoma. 
Induction of melanocyte differentiation antigen-reactive CTL employing 
dendritic cells 
The array of epitopes derived from antigens commonly expressed by 
melanoma tumors now provide a rationale for initiating multi-target tumor 
vaccination studies. However, successful activation of CD8+ cytolytic effector 
lymphocytes with anti-tumor reactivity is critically dependent on adequate 
presentation of the epitopes involved. As outlined in the introduction, dendritic cells 
are the prime antigen presenting cells for the initiation of immune responses. Using 
dendritic cells, we demonstrated the induction of tumor-specific CTL in vitro reactive 
with epitopes derived from the melanocyte differentiation antigens gplOO, tyrosinase 
and Melan A/MART-1 (chapter 5). This indicated that within the Τ cell repertoire of 
healthy donors precursor Τ lymphocytes are present that are capable of recognizing 
melanocyte differentiation antigens. 
These findings confirmed and extended observations of other investigators 
who succeeded in generating peptide-specific CTL capable of recognizing 
endogenously processed antigen using autologous В lymphoblast cells as stimulator 
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Peptide engineering to improve the immunogenicity of tumor-associated CTL 
epitopes 
The MHC class I binding-affinity and the МНС-peptide complex-stability of 
an antigenic peptide are important parameters that determine the immunogenicity of 
a CTL epitope. In order to improve the immunogenicity of two epitopes derived from 
gplOO and Melan A/MART-1 we performed amino acid substitutions within the 
epitopes and assayed HLA-A*0201-binding and complex stability on the one hand, 
and CTL recognition on the other hand (chapter 6). 
Anchor replacements towards the HLA-A*0201 peptide-binding motif applied 
to the Melan A/MART-1 27-35 epitope resulted in epitope-analogues, ALGIGILTV, 
AVGIGILTV, and AIGIGILTV, displaying improved affinities for HLA-A*0201. 
Notwithstanding the fact that these epitopes were less efficiently recognized 
compared to the wild type epitope by the CTL used in our study, these epitope-
analogues are promising candidates for anti-tumor CTL induction. 
Anchor replacements as well as an amino acid substitution at a non-anchor 
position in the gplOO 154-162 epitope gave rise to peptides that bound with higher 
affinity to HLA-A*0201 compared to the wild type epitopes, while complex stability 
was not diminished. When applying these gplOO 154-152 analogues KL.WGYWQV, 
KVWGYWQV, KIWGYWQV and KTWGYWAV in target cell sensitization assays, 
CTL reactivity could be induced at tenfold lower concentrations compared to the 
wild type epitope. Using these epitope-analogues we actually described the 
induction of epitope-analogue specific CTL. These CTL displayed reactivity with 
tumor cells endogenously processing and presenting the wild type gplOO 154-162 
epitope, demonstrating that epitope-analogues can be exploited to elicit wild type 
epitope-reactive CTL. 
The TCR used by these epitope-analogue specific CTL are currently 
investigated. Healthy donor and patient-derived CTL reactive with the gplOO 280-
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288 epitope displayed diverse TCR usage (unpublished observation, 14, and H. 
Zerour, personal communication). It is therefore likely, that these epitope-analogues 
can elicit CTL that also recognize gplOO 154-162 wild type peptide but use different 
TCR. 
Immunization of cancer patients using epitope-analogues with improved 
affinity may increase the efficacy to induce anti-tumor CTL responses. Furthermore, 
induction of multiple CTL specificities against one single tumor-associated peptide-
MHC combination will improve the chance of immunized patients to mount a 
successful tumor rejection response. Taken together, usage of epitope-analogues 
with improved immunogenicity may contribute to the development of CTL-epitope 
based vaccines in human cancer. 
Towards antigen-targeted immunotherapy of melanoma 
In addition to the array of antigens described in the introduction, undoubtedly 
more melanoma associated antigens will be identified in the near future. Detailed 
analysis of these antigens employing the MHC class I-peptide motifs and rules for 
intracellular processing, will result in a set of epitopes and epitope-analogues 
encompassing a broad range of MHC class I alleles. As a result antigen-targeted 
immunotherapy may be conceivable for most melanoma patients. Consequently, 
melanoma patients have to be selected before they can enter immunotherapy 
protocols. Eligibility criteria should include HLA-typing of the patient and analysis 
of expression levels of the defined antigens and of the HLA alleles by their tumors. 
The availability of defined tumor-associated antigens opens new ways to 
immunize cancer patients. Sofar, immunization protocols encompassed injections 
with irradiated tumor cells, or with tumor cells that were genetically modified to 
produce cytokines. It is now feasible to target defined antigens on the patients tumor 
cells by immunizing with specific peptides or intact proteins. A first way to immunize 
is the inoculation of patients with synthetic peptides. Peptides encompassing CTL 
epitopes can be endocytosed by antigen presenting cells in vivo, following in 
association with the relevant MHC class I molecules and expression at the cell 
surface. In addition, peptides may directly bind to a small fraction of empty class I 
molecules at the cell surface. Concomitant administration of cytokines that play a 
role in the induction of CTL responses such as IL-2, IL-6, IL-7 and IL-12 and GM-
CSF (15,16), may facilitate the generation of cellular anti-tumor immunity in vivo. 
Another means of facilitating the in vivo onset of an anti-tumor CTL response could 
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be the simultaneous induction of a CD4+ Τ lymphocyte response by the co-injection 
of a Τ helper epitope. Since there are but few MHC class Il-associated tumor epitopes 
known to date, an immunogenic pan-HLA-DR binding peptide was developed to 
this purpose (17). 
Whether inoculation of peptides will prove to be successful remains to be 
determined. However, preliminary data from a pilot study involving the inoculation 
of a MAGE-3, HLA-A*0101-associated peptide are quite spectacular and surprising 
(18). In this study the peptide was injected dissolved in PBS without adjuvant in 
three cycles. Of the six tumor-bearing melanoma patients who received all three 
immunizations, three displayed objective tumor regressions including one complete 
response (E.M. Rankin, personal communication). Clearly, these results are too 
preliminary to afford any conclusion regarding the efficacy of peptide-immunization, 
but they are encouraging. 
Peptide-based vaccines are attractive because of their low cost and because 
this type of vaccines is relatively easy administered to patients. Disadvantageous is 
the short half-live of peptides in vivo. Furthermore, presentation of inoculated 
peptides in vivo by non-antigen presenting cells may result in induction of anergy, 
thereby abrogating the successful onset of an anti-tumor CTL response. 
In contrast to peptide immunization, a more optimal type of vaccination 
protocol may encompass the loading of CTL epitopes onto autologous antigen 
presenting cells isolated from peripheral blood, followed by inoculation of patients 
with these peptide-pulsed antigen presenting cells. In this manner, presentation of 
the peptide by appropriate antigen presenting cells in vivo is ensured. As described 
above, dendritic cells are excellent candidates to perform this task. Recently, it was 
reported that upon injection of dendritic cells pulsed with a melanoma CTL epitope, 
the HLA-A*0101 -associated MAGE-1 peptide, MAGE-1-specific CTL could be 
isolated from the vaccination site and adjacent tumor tissue (19). From biopsies taken 
before vaccination no MAGE-1-specific CTL could be obtained, indicating that 
indeed tumor-specific CTL have been induced by dendritic cells in vivo. 
An extension of immunization protocols employing autologous antigen 
presenting cells would be to load these cells ex vivo with whole protein. The 
advantage of this setting is, that patient selection based on HLA composition is no 
longer necessary, since the HLA molecules of the antigen presenting cell will choose 
the adequate peptides to present them to Τ lymphocytes. Furthermore, this procedure 
allows the presentation of currently unknown epitopes. However, as mentioned in 
the introduction, dendritic cells may not have an efficient means of presenting 
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exogenous antigens onto МНС class I molecules. To circumvent this, methods to 
gain direct access to the MHC class I processing pathway can be utilized. 
A route of antigen administration that bypasses the in vitro isolation of 
antigen presenting cells and their loading with antigen uses recombinant viruses as 
vehicles for the in vivo delivery of antigen. Immunization with antigen-encoding 
recombinant vaccinia viruses and fowl pox viruses have been shown to elicit CTL 
responses capable of reducing tumor burden in vivo (20). More recently, replication-
deficient adenoviruses expressing the melanocyte differentiation antigens gplOO and 
Melan A/MART-1 have been constructed that could function as a vaccine to protect 
mice from challenge with a murine melanoma (21). However, undesired side-effects of 
the employment of adenoviral vectors may be the induction of dominant immune 
responses directed against viral gene products encoded by the retroviral vectors, or 
modulation of antigen processing by virally encoded proteins. Construction of 
vectors encoding only the essential viral genes needed for infection may circumvent 
these phenomena. Adenovirus-based tumor vaccines appear to be good candidates 
for use in cancer-immunotherapy, although their ultimate benefits in clinical settings 
remain to be determined. 
An alternative means of immunization would be to inoculate patients with 
heat shock proteins (HSP) isolated from melanoma tumor cells. HSPs derived from 
tumors have been shown to elicit tumor-specific immunity in animal models. Close 
examination of the isolated HSPs, HSP-70, HSP-90 and HSP-96, revealed that their 
immunogenicity could be attributed to a broad array of peptides associated to these 
proteins (22). The high specific immunogenicity of HSP-peptide complexes may 
derive from their ability to be taken up by phagocytic antigen presenting cells, 
resulting in channelling of the HSP-chaperoned peptides into the endogenous MHC 
class I presentation pathway. 
HSPs are non-polymorphic and their association with peptides is thought to 
be proximal to the association of MHC class I with peptides (23). As a result, HSP 
preparations of a particular type of tumor may contain the entire antigenic repertoire 
of that tumor regardless of the HLA phenotype of the patient. Moreover, HSP 
preparations may be used to vaccinate patients without requiring prior knowledge of 
tumor-associated antigenic epitopes. Both criteria are advantageous since most 
melanoma patients will be eligible for this type of treatment. Further elucidation of 
the cellular mechanism by which HSP-peptide complexes elicit anti-tumor immunity 
may therefore lead to a novel generation of vaccines against cancers 
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Monitoring of immunization protocols 
With defined tumor antigens it should be possible to monitor in vitro the 
efficacy of the immunization procedures. The existence of a CTL response after 
immunization seems the obvious parameter to monitor. However, the quantitative 
assessment of CTL responses against tumor antigens is a cumbersome task. Using 
autologous tumor cells, limiting dilution assays have been developed to determine 
the frequency of tumor-reactive CTL in peripheral blood of melanoma patients 
(24,25). In addition, pilot experiments indicated that it should be possible to assess 
precursor frequencies against one peptide-МНС combination, using peptide-pulsed 
cells to stimulate CD8+ Τ lymphocytes directly without prolonged in vitro culture (T. 
Wolfel, personal communication). 
Comparison of precursor frequencies before and after vaccination should 
provide a means to evaluate the effect of the immunotherapy protocol. However, 
when an anti-tumor CTL response is mounted in vivo this is not necessary reflected 
in the population of Τ lymphocytes present in peripheral blood. A majority of the 
activated tumor-reactive Τ lymphocytes may well reside within the tumors, hereby 
masking themselves for CTL precursor frequency analysis. This may be a reason 
explaining the absence of detectable MAGE-3 / HLA-A*0101-reactive CTL in 
peripheral blood of the responding patients in the peptide vaccination trial (18). An 
alternative assessment of immunity in vivo may be obtained by comparing delayed 
type hypersensitivity responses to peptide or peptide-antigen presenting cell 
inoculations prior and after immunization. 
Adoptive transfer of tumor associated antigen-reactive CTL 
An alternative approach to immunization is adoptive transfer of Τ 
lymphocytes stimulated in vitro with antigen.. Encouraging results have been 
obtained with anti-cytomegalovirus (CMV) CTL clones inoculated into bone marrow 
recipients, resulting in restoration of cellular immunity against CMV (26,27). In these 
studies persistence of the transferred CTL could be demonstrated for several months. 
It should be noted however, that the patients undergoing treatment were severely 
immunocompromised. These studies, together with the responses observed in 
melanoma patients after reinfusion of autologous in vitro expanded TIL (7,28), 
suggest that adoptive transfer based immunotherapy of cancer is feasible in man. 
118 
discussion and perspective 
However, the in vitro induction and large scale expansion of antigen specific 
CTL is laborious, and time and money-consuming. An alternative to the in vitro 
induction and selection of antigen-reactive CTL clones, is the introduction of 
antigen-specific TCR-encoding genes into unselected populations of peripheral 
blood lymphocytes. Overall however, much further research is needed to enable 
routine generation and culture of antigen-specific CTL. Therefore, to date adoptive 
transfer of tumor-specific CTL is not (yet) feasible for large scale treatment of 
melanoma and other types of cancer. 
Melanocyte differentiation antigens as targets for anti-melanoma immune 
intervention 
The isolation of cytotoxic Τ lymphocytes reactive with melanocyte lineage-
specific antigens from melanoma patients' tumor deposits and peripheral blood 
suggests that the Τ cell repertoire is not tolerized against these antigens. This notion 
was further strengthened by the in vitro induction of CTL from peripheral blood of 
healthy individuals against gplOO, tyrosinase and Melan A/MART-1. Since precursor 
Τ lymphocytes reactive with these self-antigens are present in the repertoire, it seems 
feasible to target the patients immune system to melanocyte differentiation antigens. 
However, the expression of melanocyte differentiation antigens in retina raises 
a concern about the safety of immunization procedures employing these antigens, 
since autoimmune adverse effects could be generated. Reassuring in this respect is 
the observation that most intra-ocular tissues including retina do not appear to 
express MHC class I molecules (29). In addition, the eye is an immune privileged site, 
containing a variety of potent immunosuppressive agents protecting it from 
destructive inflammatory reactions (30). Prevention of ocular autoimmunity by 
immune protection is suggested by the observation that those patients who 
developed vitiligo upon infusion of TIL reactive with melanocyte differentiation 
antigens, did not develop ophthalmic toxicity (31). Therefore, immunization of 
melanoma patients against melanocyte lineage-specific antigens may well be feasible 
without unacceptable risks. 
Whether melanocyte differentiation antigens are optimal targets for 
immunotherapy of melanoma remains to be determined. It was recently reported that 
in the repertoire HLA-A*0201-restricted melanoma-reactive CTL, a bias was 
observed for Τ cells reactive with antigens expressed on the autologous tumor but 
not on normal melanocytes (8). This suggests that the majority of HLA-A*0201-
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Concluding remarks 
The identification of tumor-associated antigens recognized by CTL initiated a 
new era in the immunotherapy of human cancer in which much emphasis is being put 
on Τ lymphocytes. Whether the concept of Τ cell-mediated immunotherapy of 
melanoma will prove to be effective, is critically dependent on the outcome of 
immunotherapy trials that will be conducted in the near future. 
In this new wave op optimism however, one should also be realistic: 
potentially anti-tumor CTL induced in vivo often have to operate in an 
immunosuppressed environment, are faced with a high tumor burden and have to 
deal with escape mechanisms exploited by tumors. In order to assess the efficacy of Τ 
cell-mediated immunotherapy protocols in the adjuvant setting, patients should be 
selected which have a low tumor burden, and which have no severely suppressed 
immune system. Data obtained with this type of studies may help to define the 
optimal protocol for the in vivo induction of Τ cell-mediated anti-tumor immunity. 
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Summary 
For proper treatment of patients bearing tumors that cannot be treated with 
radiotherapy or chemotherapy, alternative means of therapy are urgently required. A 
novel form of cancer therapy, immunotherapy, focuses on the recruitment and 
triggering of the patients' immune system to fight cancer cells. The occurrence of 
spontaneous regressions of tumor metastases as observed in some cancer patients 
demonstrates the potential of the immune system to suppress tumor growth. In 
particular, in the case of melanoma, an aggressive tumor arising from pigment 
producing cells in the skin or in the eye, spontaneous regressions are frequently 
observed. However, the existence of tumors demonstrates that protection by the 
immune system to prevent outgrowth of tumor cells is not infallible. Presumably, in a 
number of cases the immune system is improperly stimulated which may result in an 
'immune escape' of tumors. Adequate stimulation of the patients' immune system in 
vivo might revert this unresponsive state and may ultimately lead to tumor 
eradication. In the field of tumor immunology currently much research focuses on 
developing optimal means of inducing effective anti-tumor immunity in the patient. 
The specific immune system can be subdivided into the humoral and the 
cellular immune system. In the humoral system antibodies produced by В 
lymphocytes play an essential role in the eradication of soluble or cell-bound 
structures that are unknown to the immune system. The cellular immune system uses 
migrating Τ lymphocytes called CTL that can bind to tissue cells and directly lyse 
these cells upon specific recognition. From melanoma patient derived material 
antibodies reacting with the patients' own tumor cells as well as tumor-reactive 
cytotoxic Τ lymphocytes (CTL) have been obtained, indicating that both arms of the 
immune system can contribute in an anti-tumor response. 
Research described in this thesis focuses on cellular immune responses to 
melanoma tumors. CTL are thought to be the main cytolytic effector cells in anti­
tumor immune responses and therefore these cells play a pivotal role in tumor 
immunology. CTL recognize via their Τ cell receptor protein fragments (peptides) 
that are presented in MHC molecules at the cell surface of tissue cells. MHC 
molecules are present on all nucleated cells in the body and contain an enormous 
repertoire of peptides derived from cellular proteins. As a consequence of this 
presenting mechanism the peptides present in MHC molecules at the surface reflect 
the intracellular pool of proteins. Since there exists an enormous diversity of Τ cell 
receptors and since each cell displays several types of MHC molecules at the cell 
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surface, the cellular immune system is able to elicit responses against numerous 
parasite-, virus- or tumor-associated proteins. 
For a long time the nature of the antigens recognized by tumor-reactive CTL 
isolated from melanoma patients remained obscure. Knowledge of these antigens is 
crucial for the development of vaccines against melanoma and other tumors. 
Recently, a number of melanoma-associated antigens that can be recognized by 
tumor-reactive CTL have been described. Chapter 2 of this thesis describes the 
identification of the gplOO protein as a target antigen for TIL 1200, a CTL-line 
derived from a melanoma metastasis capable of lysing melanoma cells expressing the 
MHC molecule HLA-A*0201. GplOO is a differentiation antigen for cells of the 
melanocytic lineage and is also expressed on melanocytes, the normal pigment 
producing cells in the skin. The gplOO protein is the second melanoma-associated 
differentiation antigen identified as a target antigen for anti-melanoma CTL. 
Chapter 3 deals with the protein-fragments derived from the gplOO antigen 
that are recognized by TIL 1200 lymphocytes. It was found that within the TIL 1200 
line two types of Τ lymphocytes exist, both recognizing a different gplOO derived 
peptide in the context of the HLA-A*0201 molecule. These peptides, a 9-mer and a 
10-mer, are located within the gplOO protein at positions 154-162 and 457-466, 
respectively. Chapter 4 demonstrates that Pmell7, a protein closely related to the 
gplOO protein encoded by the same gene, can also be recognized by TIL 1200 
lymphocytes. Therefore, both the gplOO and the Pmell7 proteins can be used for the 
development of vaccines against melanoma. 
In chapter 5 it was investigated whether peptides derived from melanoma 
associated antigens can be used for the generation of anti-melanoma CTL in vitro. 
For this purpose dendritic cells were used. Dendritic cells are the prime antigen 
presenting cells capable of stimulating naive Τ lymphocytes. Dendritic cells used in 
this study were generated by culturing adherent monocytes for several days in the 
presence of the growth factors GM-CSF and IL-4. Subsequently these antigen 
presenting cells were loaded with HLA-A*0201-binding peptides derived from the 
differentiation antigens gplOO, tyrosinase and Melan-A/MART-1 and they were used 
to stimulate donor-derived resting Τ lymphocytes. 
Following this procedure CTL could be selected in vitro that specifically 
recognized the peptide against which they were raised, when this was provided in 
the context of the HLA-A*0201 molecule at the surface of target cells. In addition, 
these CTL were capable of lysing tumor cells presenting these peptides at the cell 
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surface themselves. This demonstrates the potential use of these peptides in vaccines 
against melanoma. 
A number of parameters affects the efficiency of inducing anti-tumor CTL in 
vitro using peptide loaded antigen presenting cells. In particular the time at which 
the antigenic peptide is displayed in the HLA-A*0201 molecule at the cell surface of 
antigen presenting cells is of critical importance. For a given peptide this is 
influenced by the binding affinity of the peptide for HLA-A*0201 and the stability 
of the peptide-HLA-A*0201 complex. In chapter 6 it was studied whether for tumor-
associated peptides these characteristics could be optimized by means of amino acid 
substitutions. Guided by peptide-binding motifs for the HLA-A*0201 molecule, 
substituted peptides were selected displaying improved affinity for HLA-A*0201 
while still being recognized by established tumor-reactive CTL. Subsequently, these 
substituted epitopes were applied to induce peptide-specific CTL in vitro using 
donor-derived Τ lymphocytes. CTL raised against mutated gplOO 154-162 peptides 
are able to recognize in addition to the mutated peptides, the 'natural' peptide when 
this is presented by melanoma tumor cells. Therefore, it can be concluded that the 
immunogenicity of given antigenic peptides can be improved by applying amino acid 
substitutions. Usage of these improved epitopes may improve the efficacy of CTL-
epitope based anti-tumor vaccines. 
Results obtained from investigations described in this thesis have contributed 
to a better understanding of what CTL can recognize at the surface of melanoma 
cells. Usage of the currently known antigenic peptides and the improved procedures 
to induce CTL against these epitopes may pave the way to the application of specific 
immunotherapy. However, a number of hurdles still have to be overcome before 
specific immunotherapy will be broadly applicable. Since tumors can escape from 
specific immune responses by ceasing to express the targeted antigen, it is necessary 
to identify several broadly expressed antigens for each type of tumor. In addition, 
further research is needed to determine the optimal means of immunization leading to 
effective anti-tumor CTL induction in melanoma patients. Furthermore, it is necessary 
to develop circumventing strategies to overcome immune escape mechanisms 
exploited by tumor cells. 
The ideal patients eligible for immunotherapy protocols carry limited amounts 
of tumor cells after removal of the primary tumor. Therefore, an early diagnosis of 
cancer is of critical importance. In these patients the immune system is not yet 
compromised and they may therefore have a fair chance of responding to 
immunotherapy. 
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Samenvatting 
Kankerpatiënten kunnen in toenemende mate succesvol worden behandeld. 
Echter, sommige typen tumoren zijn na chirurgische verwijdering van de zichtbare 
tumorhaard niet behandelbaar met radiotherapie en chemotherapie. In dit geval 
kunnen resterende tumorcellen metastases vormen en ongeremd doorgroeien. 
Hierdoor is er dringend behoefte aan een alternatieve therapie tegen deze tumoren. 
Op dit moment wordt er veel onderzoek verricht naar een nieuwe vorm van 
kankertherapie, de immunothérapie. Bij deze therapie wordt getracht het 
afweersysteem van de patient in te schakelen om tumorcellen te doden. Het spontaan 
verdwijnen van tumoren, een verschijnsel dat soms wordt waargenomen bij kanker 
patiënten, is een aanwijzing dat het immuunsysteem inderdaad tumorgroei kan 
tegengaan. Ook bij melanomen, erg kwaadaardige tumoren die kunnen ontstaan uit 
pigment producerende cellen in de huid of in het oog, worden incidenteel spontane 
regressies waargenomen. 
Het ontstaan van tumoren geeft echter aan dat het immuunsysteem geen 
afdoende bescherming biedt. Waarschijnlijk wordt in een aantal gevallen het 
afweersysteem onvoldoende of verkeerd gestimuleerd door ontstane tumorcellen 
hetgeen leidt tot tumorgroei. Het op de juiste wijze stimuleren van het 
immuunsysteem van de patient zou deze ongewenste situatie kunnen tegengaan. 
Reeds een aantal jaren wordt er veel onderzoek verricht om de juiste methode te 
vinden om optimaal anti-tumor immuniteit op te wekken in de patient. 
Het specifieke afweersysteem kan worden opgedeeld in twee deelsystemen. 
Het humorale immuunsysteem werkt via antistoffen die in het bloed worden 
uitscheiden door В lymfocyten en is vooral gericht tegen vreemde oplosbare of 
celgebonden structuren. Het cellulaire immuunsysteem maakt gebruik van Τ 
lymfocyten die zelf via het bloedbaan circuleren. Τ lymfocyten kunnen aan 
weefselcellen binden, en kunnen deze direct doden wanneer er specifieke 
herkenning optreedt. In melanoom patiënten zijn naast antistoffen gericht tegen 
tumor cellen ook tumor-specifieke cytotoxische Τ lymfocyten (CTL) gevonden, wat 
aangeeft dat beide takken van het immuunsysteem werkzaam kunnen zijn in de 
afweerrespons tegen tumoren. Het in dit proefschrift beschreven onderzoek is 
toegespitst op de cellulaire immuunrespons tegen melanomen. Met name voor CTL is 
een grote rol weggelegd in de immunothérapie, omdat deze cellen in staat worden 
geacht in het lichaam tumoren op te ruimen. CTL herkennen via hun Τ cel receptor 
eiwit-fragmenten die gepresenteerd worden in MHC moleculen op het celoppervlak 
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van lichaamscellen. Deze МНС moleculen bevinden zich op elke lichaamscel en 
bevatten een enorme diversiteit aan eiwit-fragmenten (peptiden) die afkomstig zijn 
van eiwitten die zich in de cel bevinden. Als gevolg van dit presentatie mechanisme 
bevindt zich dus op het celoppervlak van elke cel een afspiegeling van de celinhoud. 
Aangezien er een enorme diversiteit bestaat aan Τ cel receptoren (elke Τ lymfocyt 
bevat één type Τ cel receptor) en aangezien er verschillende MHC moleculen zijn op 
elke lichaamscel, is het cellulaire immuunsysteem in staat reacties te ontketenen tegen 
onnoembaar vele parasiet-, virus- of kanker-geassocieerde eiwitten. 
Voor CTL die uit melanoom patiënten geïsoleerd zijn en die in vitro 
tumorcellen kunnen doden was het een tijd lang onbekend welke peptides afkomstig 
van welke eiwitten uit de tumor cel herkend werden. Kennis van deze immunogene 
eiwitten, antigenen, is erg belangrijk voor de mogelijke ontwikkeling van vaccins 
tegen het melanoom en andere tumoren. Recent zijn een aantal melanoom-
geassocieerde antigenen die herkend kunnen worden door CTL bekend geworden. 
In het onderzoek beschreven in dit proefschrift staat de identificatie van het 
gplOO eiwit als doelwit antigeen voor melanoom-reactieve CTL centraal. We hebben 
kunnen aantonen dat een CTL-lijn, TIL 1200, in staat is melanoomcellen te doden 
mits zij het gplOO eiwit aanmaken. Het MHC (presentatie) molecuul voor deze Τ 
lymfocyten is het HLA-A*0201 molecuul. Vervolgens zijn we in staat geweest om de 
eiwit fragmenten te identificeren die afkomstig zijn van gplOO en die herkend 
worden door TIL 1200 lymfocyten. Binnen de TIL 1200-lijn blijken twee 
verschillende soorten Τ cellen voor te komen die allebei een verschillend peptide van 
gplOO kunnen herkennen in de context van het HLA-A*0201 molecuul. Verder 
hebben we kunnen aantonen dat Pmell7, een eiwit dat zeer nauw verwant is aan het 
gplOO eiwit en gecodeerd wordt door hetzelfde gen, ook herkend kan worden door 
TIL 1200 lymfocyten. Dus zowel gplOO als Pmell7 zijn eiwitten die gebruikt kunnen 
worden voor de ontwikkkeling van vaccins tegen melanomen. 
Tevens is er onderzocht of antigene peptides afkomstig van melanoom-
geassocieerde antigenen gebruikt kunnen worden om tumor-reactieve CTL te 
selecteren en te activeren. In eerste instantie hebben we gekeken of dit mogelijk is in 
vitro. Hiervoor is gebruik gemaakt van dendritische cellen, cellen die bij uitstek 
geschikt zijn om ongestimuleerde cytotoxische Τ cellen op een antigeen-specifieke 
manier aan te zetten tot groei. We hebben deze antigeen presenterende cellen 
beladen met antigene peptides van melanoom-geassocieerde antigenen zoals gplOO, 
en vervolgens hebben we ze gebruikt om rustende Τ lymfocyten afkomstig van 
gezonde donoren aan te zetten tot groei. Op deze manier is het gelukt om in vitro 
128 
samenvatting 
CTL te selecteren die specifiek het peptide herkennen waartegen ze zijn opgewekt, 
wanneer dit wordt aangeboden in HLA-A*0201 moleculen op het oppervlak van 
doelwit cellen. Deze CTL kunnen ook tumor cellen doden die zelf de antigene 
peptides op hun celoppervlak presenteren. Tevens hebben we getracht om voor 
bepaalde tumor-geassocieerde peptides de immunogeniciteit te optimaliseren door 
middel van aminozuur veranderingen. Met behulp van deze gemuteerde peptides 
zijn we er in geslaagd CTLs op te wekken die ook melanoomcellen kunnen doden. 
Dit onderzoek geeft aan dat het mogelijk is om peptides te gebruiken in vaccins 
tegen melanomen. Gebruik van geoptimaliseerde peptides in vaccins kan mogelijk 
bijdragen tot een betere inductie van melanoom reactieve CTL in het lichaam van de 
patient. 
Het gplOO eiwit komt ook voor op melanocyten, de normale pigment 
producerende cellen in de huid. Wanneer met peptides afkomstig van dit eiwit 
getracht wordt CTL responsen op te wekken in melanoom patiënten, moet rekening 
gehouden worden met de mogelijkheid dat normale pigmentcellen in de huid ook 
opgeruimd kunnen worden. Deze bijwerking die ontkleuring van de huid tot gevolg 
heeft, wordt soms ook spontaan waargenomen in melanoompatienten en duidt op 
een immuun respons gericht tegen eiwitten die voorkomen op zowel tumorcellen en 
normale melanocyten. 
De resultaten van het onderzoek beschreven in dit proefschrift hebben 
bijgedragen tot een beter begrip van wat CTL gericht tegen melanomen precies 
herkennen. Met behulp van de nu bekende antigene peptides en de steeds beter 
wordende methodes om hiermee tumor-reactieve CTL op te wekken is specifieke 
immunothérapie voor het melanoom dichterbij gekomen. Echter, de realiteit gebied te 
zeggen dat er nog vele problemen overkomen moeten worden voordat deze 
behandelingsvorm op brede schaal succesvol toegepast kan worden. Aangezien 
tumoren aan het immuunsysteem kunnen ontsnappen wanneer zij bepaalde doelwit 
antigenen niet meer tot expressie brengen, is het nodig om voor elk type tumor 
verschillende antigenen te identificeren die gebruikt kunnen worden voor het 
opwekken van CTL. Tevens is er nog veel onderzoek nodig in patiënten om te 
bepalen wat de meest efficiente immunisatie route zal zijn die leidt tot de inductie van 
tumor-reactieve CTL in het lichaam. 
129 

Nawoord 
Nu het boekje af is, is er een moment aangebroken om even stil te staan en 
terug te kijken op de afgelopen viereneenhalf jaar. Het is een hectische en vooral een 
mooie periode geweest waarin er veel gebeurd is. Direct besef ik dat het tot stand 
komen van dit boekje alleen maar mogelijk was door de hulp van velen. Met name 
Carl wil ik bedanken voor de werkomgeving die hij geschapen heeft zowel in 
Amsterdam als in Nijmegen. Carl, ik heb ontzettend veel van je geleerd. Altijd stond 
je deur open voor het bespreken van nieuwe data, en wanneer die niet altijd even 
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zaken vaak verhelderend werkt en leidt tot een beter eindresultaat. Gosse, bedankt 
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Stellingen 
behorende bij het proefschrift: 'Melanocyte lineage-specific antigen gplOO in Τ 
cell-mediated immunotherapy of melanoma'. 
1. Auto-reactieve Τ cellen specifiek voor melanocyt geassocieerde antigenen 
worden niet gedeleteerd. (dit proefschrift) 
2. Het al of niet optreden van tolerantie inductie in Τ cellen met specificiteit 
voor antigene peptides van melanocyt differentiatie antigenen is direct 
gecorreleerd met het aantal peptides dat endogeen in MHC moleculen op 
het celoppervlak gepresenteerd wordt. (V. Engelhard, wetenschappelijke 
voordracht, Taos, mei 1996) 
3. Het gebruik van de term 'laag affiene Τ cellen' is meer geschikt om de 
hoeveelheid Τ cel receptoren op het cel oppervlak aan te duiden dan om de 
affiniteit van de betreffende Τ cel receptor voor zijn МНС-peptide complex 
weer te geven. (A. Viola et al. Science 273:104. 1996) 
4. Gemuteerde antigene peptides met verhoogde immunogeniciteit kunnen 
worden gebruikt voor het opwekken van cytotoxische Τ cellen gericht 
tegen tumorcellen, (dit proefschrift) 
5. Het activeren van anti-tumor CTL in kankerpatiënten met behulp van 
vaccins gebaseerd op het gebruik van antigene peptides waarborgt nog 
geen anti-tumor respons. 
6. Een blij hart bevordert de genezing, maar een verslagen geest doet het 
gebeente verdorren. (Spreuken 17:22) 
7. Naar mate wetenschap meer gaat lijken op het nastreven van een artefact 
worden de experimenten steeds complexer. 
8. De kwaliteit van de Beerenburg van de firma Sonnema (in tegenstelling tot 
die van de firma Joustra) en de wijze waarop dit produkt via de media aan 
de man gebracht wordt, doen afbreuk aan zowel de Friese Cultuur als aan 
het fenomeen Beerenburg zelf. 
9. Sizze is in lyts bytsje, dwaan is al mear. Beide tegearre kinne bergen 
fersette. 
Lex Bakker 27 september 1996 



